<SEC-DOCUMENT>0001144204-15-068300.txt : 20151127
<SEC-HEADER>0001144204-15-068300.hdr.sgml : 20151126
<ACCEPTANCE-DATETIME>20151127134959
ACCESSION NUMBER:		0001144204-15-068300
CONFORMED SUBMISSION TYPE:	S-1
PUBLIC DOCUMENT COUNT:		8
FILED AS OF DATE:		20151127
DATE AS OF CHANGE:		20151127

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ATOSSA GENETICS INC
		CENTRAL INDEX KEY:			0001488039
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				264753208
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-208236
		FILM NUMBER:		151257881

	BUSINESS ADDRESS:	
		STREET 1:		2345 EASTLAKE AVENUE EAST
		STREET 2:		SUITE 201
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98102
		BUSINESS PHONE:		206.588.0256

	MAIL ADDRESS:	
		STREET 1:		2345 EASTLAKE AVENUE EAST
		STREET 2:		SUITE 201
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98102
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1
<SEQUENCE>1
<FILENAME>v425502_s1.htm
<DESCRIPTION>S-1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">As filed with the Securities and Exchange Commission on November 27, 2015</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Registration Statement No. 333-</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>FORM S-1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REGISTRATION STATEMENT UNDER THE SECURITIES
ACT OF 1933</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ATOSSA GENETICS INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 30%; font-size: 10pt; text-align: center"><B>Delaware</B></TD>
    <TD STYLE="width: 40%; font-size: 10pt; text-align: center"><B>3841</B></TD>
    <TD STYLE="width: 30%; font-size: 10pt; text-align: center"><B>26-4753208</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(State or other</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">jurisdiction of</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">incorporation or</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">organization)</P></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Primary Standard</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Industrial Classification</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Code Number)</P></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(I.R.S. Employer</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Identification No.)</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2300 Eastlake Ave. East, Suite 200</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Seattle, Washington 98102</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Telephone: (800) 351-3902</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address, including zip code, and telephone
number, including area code, of Registrant&rsquo;s principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Steven C. Quay</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Chairman, Chief Executive Officer and
President</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2300 Eastlake Ave. East, Suite 200</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Seattle, Washington 98102</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Telephone: (800) 351-3902</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Name, address, including zip code, and
telephone</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">number, including area code, of agent for
service)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Copies to:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Kyle Guse</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Chief Financial Officer and General Counsel</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">2300 Eastlake Ave. East, Suite 200</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Seattle, Washington 98102</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(800) 351-3902</P></TD>
    <TD STYLE="width: 50%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Ryan A. Murr</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Gibson, Dunn &amp; Crutcher, LLP</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">555 Mission Street, Suite 3000</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">San Francisco, California 94105</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Telephone: (415) 398-8200</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>Approximate date
of commencement of proposed sale to the public:</B> From time to time after this registration statement becomes effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If any of the securities
being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act
of 1933 check the following box. <FONT STYLE="font-family: Wingdings">x</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If this Form is filed
to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following
box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.
<FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If this Form is a
post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities
Act registration statement number of the earlier effective registration statement for the same offering. <FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If this Form is a
post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities
Act registration statement number of the earlier effective registration statement for the same offering. <FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Indicate by check mark
whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.
See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer&rdquo; and &ldquo;smaller reporting company&rdquo;
in Rule 12b-2 of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 30%; padding-left: 0.5in">Large accelerated filer</TD>
    <TD STYLE="width: 30%; padding-left: 0.375in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD>
    <TD STYLE="width: 30%">Accelerated filer</TD>
    <TD STYLE="width: 10%"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in">Non-accelerated filer</TD>
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD>
    <TD>Smaller reporting company</TD>
    <TD><FONT STYLE="font-family: Wingdings">x</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;(Do not check if a smaller reporting company)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The registrant is an emerging growth
company, as defined in Section 2(a) of the Securities Act. This Registration Statement complies with the requirements that apply
to an issuer that is an emerging growth company.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The registrant hereby amends this Registration
Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment
which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of
the Securities Act of 1933, as amended, or until the Registration Statement shall become effective on such date as the Securities
and Exchange Commission, acting pursuant to said Section 8(a), may determine.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The registrant is an emerging growth
company, as defined in Section 2(a) of the Securities Act. This Registration Statement complies with the requirements that apply
to an issuer that is an emerging growth company.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CALCULATION OF REGISTRATION FEE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Title of each class of</B> </FONT><BR>
<FONT STYLE="font-size: 10pt"><B>securities to be registered</B></FONT></TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Amount</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>to be</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>registered</B></FONT></TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Proposed</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>maximum</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>offering</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>price</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>per share</B></FONT></TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Proposed</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>maximum</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>aggregate offering</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>price</B></FONT></TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Amount of</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>registration</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>fee</B></FONT></TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 46%"><FONT STYLE="font-size: 10pt">Common Stock, par value $0.001 per share</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">6,086,207 </FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">0.47</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">2,860,517</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">288</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1) Represents 6,086,207 shares of Common
Stock, par value $0.001 per share (the &ldquo;<B><I>Common Stock</I></B>&rdquo;) that are issuable pursuant to a common stock purchase
agreement with the selling stockholder named herein. Pursuant to Rule 416(a) of the Securities Act of 1933, as amended, this Registration
Statement also covers any additional shares of Common Stock which may become issuable to prevent dilution from stock splits, stock
dividends and similar events.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2) Pursuant to Rule 457(c), calculated on the basis of the average of the high and low prices per share
of the registrant&rsquo;s Common Stock reported on the NASDAQ Capital Market on November 25, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>The registrant hereby
amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall
file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance
with Section 8(a) of the Securities Act of 1933, as amended, or until the Registration Statement shall become effective on such
date as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: red"><B>The information in this
prospectus is not complete and may be changed. The selling stockholder may not sell these securities until the registration statement
filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities, and the
selling stockholder is not soliciting offers to buy these securities, in any state where the offer or sale of these securities
is not permitted.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: red"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>PRELIMINARY PROSPECTUS, SUBJECT TO COMPLETION</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>DATED _________________, 2015</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="tpg04.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>6,086,207</B> <B>Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus relates
to the sale of up to 6,086,207 shares of our Common Stock by Aspire Capital Fund, LLC, an Illinois limited liability company (&ldquo;<B><I>Aspire
Capital</I></B>&rdquo; or the &ldquo;<B><I>Selling Stockholder</I></B>&rdquo;). The prices at which the Selling Stockholder may
sell the shares will be determined by the prevailing market price for the shares or in negotiated transactions. We will not receive
proceeds from the sale of the shares by the Selling Stockholder. However, we may receive proceeds of up to $25.0 million from the
sale of our Common Stock to the Selling Stockholder, pursuant to a common stock purchase agreement entered into with the Selling
Stockholder on November 11, 2015 (the &ldquo;<B><I>Purchase Agreement</I></B>&rdquo;), once the registration statement, of which
this prospectus is a part, is declared effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Selling Stockholder
is an &ldquo;underwriter&rdquo; within the meaning of the Securities Act of 1933, as amended. We will pay the expenses of registering
these shares, but all selling and other expenses incurred by the Selling Stockholder will be paid by the Selling Stockholder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Common Stock trades
on the NASDAQ Capital Market, or NASDAQ, under the ticker symbol &ldquo;ATOS.&rdquo; On November 25, 2015, the last reported sale
price per share of our common stock was $0.48 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Investing in our
securities involves a high degree of risk. See &ldquo;Risk Factors&rdquo; on page 7 of this prospectus.</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Neither the Securities
and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the
adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">The date of this prospectus
is _________________, 2015</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="width: 90%"><A HREF="#a_001"><FONT STYLE="font-family: Times New Roman, Times, Serif">PROSPECTUS SUMMARY</FONT></A></TD>
    <TD STYLE="width: 10%; text-align: right">1</TD></TR>
<TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_002">RISK FACTORS</A></FONT></TD>
    <TD STYLE="text-align: right">7</TD></TR>
<TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD><A HREF="#a_003"><FONT STYLE="font-family: Times New Roman, Times, Serif">USE OF PROCEEDS</FONT></A></TD>
    <TD STYLE="text-align: right">10</TD></TR>
<TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD><A HREF="#a_004"><FONT STYLE="font-family: Times New Roman, Times, Serif">DIVIDEND POLICY</FONT></A></TD>
    <TD STYLE="text-align: right">10</TD></TR>
<TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD><A HREF="#a_005"><FONT STYLE="font-family: Times New Roman, Times, Serif">SELLING STOCKHOLDER</FONT></A></TD>
    <TD STYLE="text-align: right">10</TD></TR>
<TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD><A HREF="#a_006"><FONT STYLE="font-family: Times New Roman, Times, Serif">THE ASPIRE CAPITAL TRANSACTION</FONT></A></TD>
    <TD STYLE="text-align: right">12</TD></TR>
<TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD><A HREF="#a_007"><FONT STYLE="font-family: Times New Roman, Times, Serif">PLAN OF DISTRIBUTION</FONT></A></TD>
    <TD STYLE="text-align: right">17</TD></TR>
<TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">PRINCIPAL STOCKHOLDERS</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD><A HREF="#a_008"><FONT STYLE="font-family: Times New Roman, Times, Serif">DESCRIPTION OF SECURITIES TO BE REGISTERED</FONT></A></TD>
    <TD STYLE="text-align: right">19</TD></TR>
<TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD><A HREF="#a_009"><FONT STYLE="font-family: Times New Roman, Times, Serif">DISCLOSURE OF COMMISSION POSITION ON INDEMNIFICATION FOR SECURITIES ACT LIABILITIES</FONT></A></TD>
    <TD STYLE="text-align: right">20</TD></TR>
<TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD><A HREF="#a_010"><FONT STYLE="font-family: Times New Roman, Times, Serif">LEGAL MATTERS</FONT></A></TD>
    <TD STYLE="text-align: right">20</TD></TR>
<TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD><A HREF="#a_011"><FONT STYLE="font-family: Times New Roman, Times, Serif">EXPERTS</FONT></A></TD>
    <TD STYLE="text-align: right">20</TD></TR>
<TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD><A HREF="#a_012"><FONT STYLE="font-family: Times New Roman, Times, Serif">WHERE YOU CAN FIND ADDITIONAL INFORMATION</FONT></A></TD>
    <TD STYLE="text-align: right">20</TD></TR>
<TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD><A HREF="#a_013"><FONT STYLE="font-family: Times New Roman, Times, Serif">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</FONT></A></TD>
    <TD STYLE="text-align: right">21</TD></TR>
<TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD><A HREF="#a_014"><FONT STYLE="font-family: Times New Roman, Times, Serif">PART II INFORMATION NOT REQUIRED IN PROSPECTUS</FONT></A></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">II-1</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD><A HREF="#a_015"><FONT STYLE="font-family: Times New Roman, Times, Serif">SIGNATURES</FONT></A></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">II-5</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD><A HREF="#a_016"><FONT STYLE="font-family: Times New Roman, Times, Serif">EXHIBIT INDEX</FONT></A></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">II-6</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You should read this
prospectus, any applicable prospectus supplement and the information incorporated by reference in this prospectus before making
an investment in the securities of Atossa Genetics Inc. See &ldquo;Where You Can Find Additional Information&rdquo; on page 20
for more information. You should rely only on the information contained in or incorporated by reference in this prospectus or
a prospectus supplement. The Company has not authorized anyone to provide you with different information. This document may be
used only in jurisdictions where offers and sales of these securities are permitted. You should assume that information contained
in this prospectus, or in any document incorporated by reference, is accurate only as of any date on the front cover of the applicable
document. Our business, financial condition, results of operations and prospects may have changed since that date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTE REGARDING FORWARD-LOOKING STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus and the documents incorporated
by reference into it contain, in addition to historical information, certain information, assumptions and discussions that may
constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the &ldquo;<B><I>Securities
Act</I></B>&rdquo;) and Section 21E of the Securities Exchange Act of 1934, as amended (the &ldquo;<B><I>Exchange Act</I></B>&rdquo;).
We have made these statements in reliance on the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
These statements are subject to certain risks and uncertainties, which could cause actual results to differ materially from those
projected or anticipated. Although we believe our assumptions underlying our forward-looking statements are reasonable as of the
date of this prospectus, we cannot assure you that the forward-looking statements set out in this prospectus will prove to be accurate.
We typically identify these forward-looking statements by the use of forward-looking words such as &ldquo;expect,&rdquo; &ldquo;potential,&rdquo;
&ldquo;continue,&rdquo; &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;should,&rdquo; &ldquo;could,&rdquo; &ldquo;would,&rdquo;
&ldquo;seek,&rdquo; &ldquo;intend,&rdquo; &ldquo;plan,&rdquo; &ldquo;estimate,&rdquo; &ldquo;anticipate&rdquo; or the negative
version of those words or other comparable words. Forward-looking statements contained in this prospectus include, but are not
limited to, statements about:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 3%; text-align: justify">&bull;</TD>
    <TD STYLE="width: 94%; text-align: justify">whether we maintain our clearances from the U.S. Food and Drug Administration, or FDA, and foreign regulatory bodies, and the CE Certificates of Conformity granted by our notified body, to sell, market and distribute our medical devices;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&bull;</TD>
    <TD STYLE="text-align: justify">whether we can achieve our revenue forecast and other financial projections for 2015;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&bull;</TD>
    <TD STYLE="text-align: justify">our ability to successfully commercialize the FullCYTE Breast Aspirator in the United States and our ForeCYTE Breast Aspirator outside the United States;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&bull;</TD>
    <TD STYLE="text-align: justify">our ability to successfully continue selling and servicing Pharmacogenomics and NAF cytology testing in our laboratory;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&bull;</TD>
    <TD STYLE="text-align: justify">our ability to successfully develop and commercialize our pharmaceutical candidates, including Afimoxifene Topical Gel and our ability to manufacture sufficient quantities of the active ingredients, enroll and successfully complete clinical studies and obtain necessary approvals from the FDA and other regulatory authorities;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&bull;</TD>
    <TD STYLE="text-align: justify">our ability to successfully sell our products and services at currently expected prices or otherwise at prices acceptable to us;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&bull;</TD>
    <TD STYLE="text-align: justify">our ability to successfully develop and commercialize new tests, tools and treatments currently in development and in the time frames currently expected;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&bull;</TD>
    <TD STYLE="text-align: justify">our ability to maintain our business relationships, including with our distributors, suppliers and customers, while we launch and commercialize the FullCYTE Breast Aspirator in the United States and ForeCYTE Breast Aspirator and laboratory tests outside the United States;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&bull;</TD>
    <TD STYLE="text-align: justify">our ability to engage third party suppliers to manufacture the ForeCYTE Breast Aspirator, FullCYTE Breast Aspirator, FullCYTE Microcatheter, other devices under development and their components at quantities and costs acceptable to us;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&bull;</TD>
    <TD STYLE="text-align: justify">our ability to satisfy ongoing FDA, European Union (EU) and foreign requirements for manufacturing, distributing, and promoting the FullCYTE Breast Aspirator, NAF cytology test and FullCYTE Microcatheter and to obtain regulatory approvals, clearances and CE Certificate of Conformity for our other products and services in development;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%">&bull;</TD>
    <TD STYLE="width: 94%; text-align: justify">our ability to successfully defend ongoing litigation, including the securities class action law suit filed against us on October 10, 2013, and other similar complaints that may be brought in the future, in a timely manner and within the coverage, scope and limits of our insurance policies;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&bull;</TD>
    <TD STYLE="text-align: justify">the benefits and clinical accuracy of our laboratory tests, including the NAF cytology and Pharmacogenomics tests;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&bull;</TD>
    <TD STYLE="text-align: justify">our ability to establish and maintain intellectual property rights covering our products and services;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&bull;</TD>
    <TD STYLE="text-align: justify">the willingness of health insurance companies, including those who are members of the MultiPlan, FedMed and HealthSmart networks, and other third party payors to approve our products and services for coverage and reimbursement;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&bull;</TD>
    <TD STYLE="text-align: justify">our ability to establish and maintain an independent sales representative force, including with our current and future distributors and their sub-distributors, to market our current products and services and those that we may develop;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&bull;</TD>
    <TD STYLE="text-align: justify">our expectations regarding, and our ability to satisfy, federal, state and foreign regulatory requirements;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&bull;</TD>
    <TD STYLE="text-align: justify">the accuracy of our estimates of the size and characteristics of the markets that our products and services may address;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&bull;</TD>
    <TD>our expectations as to future financial performance, expense levels and liquidity sources;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&bull;</TD>
    <TD>our ability to attract and retain key personnel;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&bull;</TD>
    <TD STYLE="text-align: justify">our ability to sell additional shares of our common stock to Aspire Capital under the terms of our purchase agreement with them; and</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&bull;</TD>
    <TD STYLE="text-align: justify">our ability to obtain, maintain and defend our intellectual property rights covering our devices, specimens, collection kits, diagnostic tests and compositions.</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">This prospectus also contains estimates
and other statistical data provided by independent parties and by us relating to market size and growth and other industry data.
These and other forward-looking statements made in this prospectus are presented as of the date on which the statements are made.
We have included important factors in the cautionary statements included in this prospectus, particularly in the section titled
&ldquo;Risk Factors,&rdquo; that we believe could cause actual results or events to differ materially from the forward-looking
statements that we make. Our forward-looking statements do not reflect the potential impact of any new information, future events
or circumstances that may affect our business after the date of this prospectus. Except as required by law, we do not intend to
update any forward-looking statements after the date on which the statement is made, whether as a result of new information, future
events or circumstances or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_001"></A>PROSPECTUS SUMMARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>The following summary
of our business highlights certain of the information contained elsewhere in or incorporated by reference into this prospectus.
Because this is only a summary, however, it may not contain all of the information that may be important to you. You should carefully
read the following summary together with the more detailed information regarding our Company and the securities being sold in this
offering, including &ldquo;Risk Factors&rdquo; and other information incorporated by reference herein.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Our Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a healthcare
company focused on the development of locally-administered pharmaceuticals for the treatment of pre-cancer and early stage breast
cancer. Our leading pharmaceutical under development is Afimoxifene Topical Gel, or AfTG, which is in Phase II clinical development.
We are also planning a Phase II clinical trial using our patented intraductal Microcatheters to deliver fulvestrant to treat ductal
carcinoma in-situ, or DCIS, and breast cancer. We have also developed and are commercializing proprietary laboratory tests and
medical devices. Our laboratory tests are being developed and performed by our wholly-owned subsidiary, The National Reference
Laboratory for Breast Health, Inc., or the &ldquo;NRLBH.&rdquo; The NRLBH has developed and is currently marketing nipple aspirate
fluid, or NAF, cytology tests and pharmacogenomics tests.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In May 2015, we acquired the worldwide exclusive rights to develop and commercialize AfTG for the potential
treatment and prevention of hyperplasia of the breast and the rights to expand the license to other indications including breast
cancer (which would require that we pay milestone payments for each additional indication). AfTG has been used in 16 Phase I and
Phase II studies conducted in a variety of indications with over 450 patients. We are in the process of re-establishing the clinical
supply of AfTG and plan to commence a Phase II clinical trial in mid-2016. The National Cancer Institute, Division of Cancer Prevention,
has approved a Letter of Intent submitted by a member of the Consortia for Cancer Prevention Clinical Trials Program for the study
of AfTG in women with DCIS. The Consortia includes five major medical research centers: the University of Arizona, Northwestern
University, Mayo Clinic Foundation, M. D. Anderson Cancer Center and the University of Wisconsin.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In October 2015 the
FDA accepted our investigational new drug application, or IND, to commence a Phase II clinical study using fulvestrant administered
via our patented intraductal Microcatheters to treat DCIS and breast cancer. We expect this study will be performed by Columbia
University Medical Center and will commence in December 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our medical devices
include the ForeCYTE Breast Aspirator for distribution outside the United States and the FullCYTE Breast Aspirator for the U.S.
market. These devices are intended for the collection of nipple aspirate fluid, or NAF, for cytological testing at a laboratory.
The current version of the ForeCYTE Breast Aspirator is CE-marked and the FullCYTE Breast Aspirator has been cleared by the FDA.
Other devices under development include intraductal Microcatheters for the potential administration of targeted pharmaceuticals,
and various tools for potential use by breast surgeons.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our key objectives
are:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(1) <U>Pharmaceutical
Development</U>: We plan to advance our pharmaceutical candidates through Phase II trials. A Phase II study of fulvestrant administered
via our patented intraductal Microcatheters is planned to commence in December 2015. A Phase II study of AfTG is planned to begin
enrollment in the mid-2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(2) <U>Laboratory Tests:</U>
We plan to grow our revenue by promoting the pharmacogenomics test currently being offered by the NRLBH, and by developing and
commercializing additional laboratory tests. We reported total gross revenue of $5.3 million for the nine months ended September
30, 2015, substantially all of which was from pharmacogenomics testing. In October 2015, we hired four additional fulltime sales
and marketing professionals and beginning in October 2015 substantially all of our internal sales and marketing resources are being
devoted to our pharmacogenomics test.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(3) <U>Breast Aspirators:</U>
Our FullCYTE Breast Aspirator is available in the United States through our distributors, which are currently Thermo Fisher Scientific
and Henry Schein Medical. Our ForeCYTE Breast Aspirator is available in the EU and related markets through Rhenus Logistics. We
plan to commence approximately three clinical studies in the EU and related markets of our ForeCYTE device to demonstrate clinical
utility of the ForeCYTE device and/or to identify biomarkers in NAF that, subject to additional regulatory clearances, may enhance
clinical utility of the device and the laboratory test of the NAF specimen. In September 2015, we received approval from the institutional
review board to commence the first of these studies using the ForeCYTE device in Israel. In November 2015, we submitted an application
with the American Medical Association for a CPT code for the collection NAF in doctor&rsquo;s offices. This is a critical step
in helping to acquire third-party reimbursement for the collection procedure and is an important element in generating testing
procedures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our common stock is
currently quoted on The NASDAQ Capital Market under the symbol &ldquo;ATOS.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our Pharmaceutical Programs Under Development</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have two locally-administered pharmaceutical programs under
development: AfTG, which the patient applies daily directly to the breast, and a drug called fulvestrant that a surgeon administers
through our patented intraductal Microcatheters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Afimoxifene Topical Gel (AfTG)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left">Overview</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We hold the worldwide
exclusive rights to develop and commercialize AfTG for the potential treatment and prevention of hyperplasia of the breast. The
active pharmaceutical ingredient in AfTG is Afimoxifene (4-hydroxytamoxifen), which is an active metabolite of tamoxifen. Afimoxifene
is an anti-estrogen with an affinity for estrogen receptor that is up to 50 fold higher compared with that of tamoxifen. AfTG
is a proprietary transdermal gel formulation of Afimoxifene protected by 10 patent families. We are evaluating AfTG for potential
use in several patient populations: high risk women as determined by family history, etc.; women with high breast density; and
women with a biopsy showing either atypical hyperplasia or DCIS. We plan to start enrolling patients in a Phase 2 study of AfTG
in mid-2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">AfTG can be dispensed
from a convenient metered-dose container. We have rights to a comprehensive preclinical pharmacology and toxicology package on
AfTG and its manufacturing CMC package is expected to be sufficient to support our Phase 2 and 3 programs. A total of 16 Phase
1 and Phase 2 studies have been conducted in a variety of indications in the United States, United Kingdom, France, Poland, and
Czech Republic. These studies enrolled over 450 patients total, and results were published in leading medical journals such as
the Journal of Clinical Oncology (J Clin Oncol 2005;23:2980-87), Clinical Cancer Research (Clin Cancer Res 2014;20:3672-82), and
Breast Cancer Research and Treatment (Breast Cancer Res Treat 2007;106:389-97).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left">Potential Funding by NCI</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The National Cancer
Institute, Division of Cancer Prevention, has approved a Letter of Intent submitted by a member of the Consortia for Cancer Prevention
Clinical Trials Program for the study of AfTG in women with DCIS. The Consortia includes five major medical research centers: the
University of Arizona, Northwestern University, Mayo Clinic Foundation, M. D. Anderson Cancer Center and the University of Wisconsin.
The next step is for the academic investigator to develop a clinical protocol. If this program is ultimately approved, the majority
of the cost of the clinical trial is expected to be paid for by the NCI. This program could provide major clinical validation of
AfTG by the NCI and leading breast cancer academic investigators, and having the NCI pay for the study would be less costly than
if we were to pay for the study ourselves.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in">Existing Data on AfTG</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The results of previous studies show that the efficacy of oral tamoxifen in preventing cancer in the study
patient populations varies from a low of about 50% to a high of almost 85%. The cancers that did occur in the patients in these
studies had a common theme: none of them were estrogen receptor positive. So, the most common kind of breast cancer, estrogen positive,
is almost entirely prevented by oral tamoxifen. The most common form of male breast cancer is also estrogen receptor positive,
so there is potential for this currently underserved breast cancer population.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These studies demonstrate that tamoxifen is quite effective
in preventing breast cancer in these patient populations. We hope that our studies will show that AfTG is also effective but because
it is delivered topically rather than orally and we hope that our studies will demonstrate that AfTG does not cause strokes, cataracts,
blood clots in the legs and lungs, and cancer of the uterus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In a previous study
done by the National Cancer Institute and academic centers in women with DCIS, oral tamoxifen or AfTG was given to women for a
month and the amount of drug was measured in the breast, and in the blood where it causes toxicity. The results show that there
were similar amounts of active drug in the breast of both groups but &lt;5% of drug in the blood with our gel compared to the
oral tamoxifen. The blood markers of stroke, blood clots, and uterine cancer were increased by oral tamoxifen but not AfTG. And
the biomarker in the breast of blocking estrogen effect, called Ki-67, showed similar blockage of cell growth.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in">Summary of our Rights to AfTG</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These AfTG rights were
granted to us pursuant to a May 14, 2015, Intellectual Property License Agreement with Besins Healthcare Luxembourg SARL. The agreement
requires that we pay a royalty of 8% to 9% of net sales for the first 15 years of commercialization. We have the non-exclusive
right to also develop AfTG for breast cancer and other breast diseases, which would require the payment of the following milestone
payments for these additional indications: (i) $5,000,000 for the exclusive right to review, access, and reference a Besins investigational
new drug application (IND) for each additional indication, and (ii) $20,000,000 when we commences a Phase 3 clinical trial for
each additional indication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If and when we decide to sublicense its
rights to commercialize the AfTG in a country in the territory, Besins has the right of first refusal to commercialize the AfTG
on a country-by-country basis in countries where Besins has a marketing presence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The agreement automatically expires on
a country-by-country basis fifteen years after the first commercial sale of AfTG in the particular country. The agreement may be
terminated (i) by either party upon a material breach of the agreement that is not cured by the breaching party, (ii) by mutual
agreement of the parties, (iii) by Atossa at its discretion if it elects to stop developing or commercializing AfTG, (iv) by Besins
on a country-by-country basis or indication-by-indication basis if we fail to commercialize or commence commercial sales within
a specified time, or (v) by Besins if we fail to accomplish any aspect of the development plan within six months of target date
set forth in the development plan. The development plan covers an 18-month period and is required to be updated by us every six
months during the term of the agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in">Next steps with AfTG</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have engaged AAIPharma/Cambridge Major
Laboratories to manufacture AfTG. They are an experienced pharmaceutical manufacturer with a good FDA track record and we are confident
will produce the cGMP quantities in a timely manner to support our study plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our next step with our AfTG program is to
get feedback from the FDA on potential clinical programs. This will occur in the first quarter of 2016. Our goal is to enroll the
first patient in a trial in mid-2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Intraductal Fulvestrant Administered
via our Microcatheters</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Fulvestrant is an FDA-approved drug for
metastatic breast cancer. It is given as a monthly injection of two big shots, typically given into the buttocks. In 2012 a published
study documented that the single dose cost of intramuscular Fulvestrant was approximately $12,000, which is over $140,000 per patient
per year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">One potential market for intraductal therapy is to take advantage
of the large difference in the amount of drug that gets into the tissue with the intraductal administration versus the intramuscular
injection. One analysis suggests that the dug levels in tissue might be over 20,000-times higher with the intraductal route. This
provides the potential to test a &lsquo;one and done&rsquo; intraductal treatment modality instead of the monthly injections and
with potentially higher tissue levels than are possible with intramuscular administration which should represent a significant
cost savings to the healthcare system.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have an issued patent for the intraductal
use of fulvestrant as well as many other pharmaceuticals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A second potential indication for intraductal
fulvestrant is in the neoadjuvant setting, meaning that the drug would be delivered before the primary treatment of surgery. High
drug concentration at the site of the tumor and lack of systemic exposure and subsequent toxicity could represent real treatment
advances. The current neoadjuvant schedules can run for three months before surgery and the ability to shorten that by one or even
two months has immense value for the patient and the healthcare system.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will be developing the clinical path
and indications we intend to follow over the next three months and then will request an FDA meeting during the first quarter of
2016. We do not yet have FDA&rsquo;s thoughts but our preliminary analysis, subject to FDA feedback, is that the intraductal fulvestrant
program could qualify for designation under the 505(b)(2) status. This would allow us to file with clinical data only and without
having to perform additional, significant clinical or pre-clinical studies. So the path to market is both faster and less expensive
than a standard NDA program. &#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">To support this development program, we
have successfully completed the clinical build of micro-catheters for the clinical trial program. The FDA has also issued a &ldquo;Safe
to Proceed&rdquo; letter for our first Investigational New Drug application or IND for this study to begin. We expect that the
Columbia University Medical Center Breast Cancer Program will be conducting our first clinical study of intraductal fulvestrant
and we hope to enroll the first patient in December 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our Laboratory, the NRLBH</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0.5in; text-align: justify">The NRLBH, located in Seattle, Washington, is certified under
CLIA and ISO 15189:2012 and is certified by the College of American Pathologists. We believe the NRLBH is one of fewer than ten
laboratories in the United States to hold the ISO 15189:2012 certification and it was the first commercial lab in the country to
offer enhanced pharmacogenomics testing based on the Luminex xTAG platform. Substantially all of our revenue in 2015 has been generated
by the NRLBH from its pharmacogenomics test services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">An adverse Medicare local coverage determination, or LCD, was
made on June 22, 2015 that limits the medical conditions and drugs that are covered by Medicare for our pharmacogenomics tests.
As a result, our revenue from Medicare as well as from commercial payers has been negatively impacted. Due to the uncertainty around
the impact that this change is having and could continue to have on our business, we are not providing a revenue forecast for 2015
and have withdrawn all forecasts that we previously provided.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The NRLBH has in-network arrangements with
Meridian Health Plan of Michigan and Washington Medicaid and is in the process of securing additional in-network arrangements with
Medicaid and commercial payers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Implications of being an Emerging Growth
Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are an &ldquo;emerging
growth company,&rdquo; as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, and, for as long as we continue
to be an &ldquo;emerging growth company,&rdquo; we may choose to take advantage of exemptions from various reporting requirements
applicable to other public companies but not to &ldquo;emerging growth companies,&rdquo; including, but not limited to, not being
required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, reduced disclosure
obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements
of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously
approved. We could be an &ldquo;emerging growth company&rdquo; for up to five years, or until the earliest of (i) the last day
of the first fiscal year in which our annual gross revenues exceed $1 billion, (ii) the date that we become a &ldquo;large accelerated
filer&rdquo; as defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended, which would occur if the market value
of our common stock that is held by non-affiliates exceeds $700 million as of the last business day of our most recently completed
second fiscal quarter, or (iii) the date on which we have issued more than $1 billion in non-convertible debt during the preceding
three-year period. We are choosing to &ldquo;opt out&rdquo; of the extended transition periods available under the JOBS Act for
complying with new or revised accounting standards, and intend to take advantage of the other exemptions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Corporate Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We were incorporated
in Delaware in April 2009. Our principal executive offices are located at 2300 Eastlake Ave. East, Suite 200, Seattle, Washington
98102 and our telephone number is (800) 351-3902. Our corporate website is located at <I>www.atossagenetics.com</I> and our laboratory
website is located at <I>www.nrlbh.com</I>. Information contained on, or that can be accessed through, our websites is not a part
of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">MASCT is our registered
trademark and our name and logo are our trademarks. FullCYTE, NextCYTE and ArgusCYTE are our service marks. This prospectus also
includes additional trademarks, trade names and service marks of third parties, which are the property of their respective owners.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>THE OFFERING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 25%"><FONT STYLE="font-size: 10pt"><B>Common stock covered by this Prospectus: </B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 73%"><FONT STYLE="font-size: 10pt">Up to 6,086,207 shares of Common Stock.</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><B>Common stock outstanding as of September 30, 2015: </B></FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">30,446,260 shares.</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><B>Use of proceeds:</B></FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">The Selling Stockholder will receive all of the proceeds from the sale of the shares offered for sale by it under this prospectus. We will not receive proceeds from the sale of the shares by the Selling Stockholder. However, we may receive up to $25.0 million in proceeds from the sale of our Common Stock to the Selling Stockholder under the Purchase Agreement described below. Any proceeds from the Selling Stockholder that we receive under the Purchase Agreement are expected be used for working capital and general corporate purposes. See &ldquo;Use of Proceeds.&rdquo;</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><B>Risk factors: </B></FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">The shares offered hereby involve a high degree of risk. See &ldquo;Risk Factors&rdquo; beginning on page 7.</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><B>Dividend policy:</B></FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">We currently intend to retain any future earnings to fund the development and growth of our business. Therefore, we do not currently anticipate paying cash dividends on our Common Stock.</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><B>Trading Symbol:</B></FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Our Common Stock currently trades on the NASDAQ Capital Market under the symbol &ldquo;ATOS&rdquo;.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Our Common Stock Purchase Agreement
with Aspire Capital Fund, LLC</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 11, 2015,
we entered into a common stock purchase agreement (referred to in this prospectus as the &ldquo;<B><I>Purchase Agreement</I></B>&rdquo;),
with Aspire Capital Fund, LLC, an Illinois limited liability company (referred to in this prospectus as &ldquo;<B><I>Aspire Capital</I></B>&rdquo;
or the &ldquo;<B><I>Selling Stockholder</I></B>&rdquo;), which provides that, upon the terms and subject to the conditions and
limitations set forth therein, Aspire Capital is committed to purchase up to an aggregate of $25.0 million of our shares of Common
Stock over the approximately 30-month term of the Purchase Agreement. Concurrently with entering into the Purchase Agreement, we
also entered into a registration rights agreement with Aspire Capital (referred to in this prospectus as the &ldquo;<B><I>Registration
Rights Agreement</I></B>&rdquo;), in which we agreed to file one or more registration statements, including the registration statement
of which this prospectus is a part, as permissible and necessary to register under the Securities Act of 1933, as amended, or the
Securities Act, the sale of the shares of our Common Stock that have been and may be issued to Aspire Capital under the Purchase
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of November 11,
2015, there were 30,446,260 shares of our Common Stock outstanding (25,667,728 shares held by non-affiliates), excluding the 6,086,207
shares offered that have not been issued but may become issuable to Aspire Capital pursuant to the Purchase Agreement. If all
of the 6,086,207 shares of our Common Stock offered hereby were issued and outstanding as of the date thereof, such shares would
represent 19.99% of the total Common Stock outstanding or 23.71% of the non-affiliate shares of Common Stock outstanding as of
the date we entered into the Purchase Agreement. The number of shares of our Common Stock ultimately offered for sale by Aspire
Capital is dependent upon the number of shares purchased by Aspire Capital under the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of November 27, 2015
there were 30,446,260 shares of our Common Stock outstanding (25,667,728 shares held by non-affiliates), excluding the 6,086,207
shares offered by this prospectus that have not been issued but may become issuable to Aspire Capital pursuant to the Purchase
Agreement. The number of shares of our Common Stock ultimately offered for sale by Aspire Capital is dependent upon the number
of shares purchased by Aspire Capital under the Purchase Agreement.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Purchase
Agreement and the Registration Rights Agreement, we are registering 6,086,207 shares of our Common Stock under the Securities Act,
which we may issue to Aspire Capital after this registration statement is declared effective under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">After the Securities
and Exchange Commission has declared effective the registration statement of which this prospectus is a part, on any trading day
on which the closing sale price of our common stock exceeds $0.10, we have the right, in our sole discretion, to present Aspire
Capital with a purchase notice (each, a &ldquo;<B><I>Purchase Notice</I></B>&rdquo;), directing Aspire Capital (as principal) to
purchase up to 150,000 shares of our common stock per trading day, provided that the aggregate price of such purchase shall not
exceed $500,000 per trading day, up to $25.0 million of our Common Stock in the aggregate at a per share price (the &ldquo;<B><I>Purchase
Price</I></B>&rdquo;) calculated by reference to the prevailing market price of our common stock (as more specifically described
below).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, on any
date on which we submit a Purchase Notice for 150,000 shares to Aspire Capital and the closing sale price of our stock is equal
to or greater than $0.50 per share of Common Stock, we also have the right, in our sole discretion, to present Aspire Capital with
a volume-weighted average price purchase notice (each, a &ldquo;<B><I>VWAP Purchase Notice</I></B>&rdquo;) directing Aspire Capital
to purchase an amount of stock equal to up to 30% of the aggregate shares of our Common Stock traded on the NASDAQ on the next
trading day (the &ldquo;<B><I>VWAP Purchase Date</I></B>&rdquo;), subject to a maximum number of shares we may determine (the &ldquo;<B><I>VWAP
Purchase Share Volume Maximum</I></B>&rdquo;) and a minimum trading price (the &ldquo;<B><I>VWAP Minimum Price Threshold</I></B>&rdquo;)
(as more specifically described below). The purchase price per share pursuant to such VWAP Purchase Notice (the &ldquo;<B><I>VWAP
Purchase Price</I></B>&rdquo;) is calculated by reference to the prevailing market price of our Common Stock (as more specifically
described below).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Purchase Agreement
provides that the Company and Aspire Capital shall not affect any sales under the Purchase Agreement on any purchase date where
the closing sale price of our Common Stock is less than $0.10 per share (the &ldquo;<B><I>Floor Price</I></B>&rdquo;). This Floor
Price and the respective prices and share numbers in the preceding paragraphs shall be appropriately adjusted for any reorganization,
recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction. There are no trading volume
requirements or restrictions under the Purchase Agreement, and we will control the timing and amount of any sales of our common
stock to Aspire Capital. Aspire Capital has no right to require any sales by us, but is obligated to make purchases from us as
we direct in accordance with the Purchase Agreement. There are no limitations on use of proceeds, financial or business covenants,
restrictions on future fundings, rights of first refusal, participation rights, penalties or liquidated damages in the Purchase
Agreement. Aspire Capital may not assign its rights or obligations under the Purchase Agreement. The Purchase Agreement may be
terminated by us at any time, at our discretion, without any penalty or cost to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The issuance of the
all shares to Aspire Capital under the Purchase Agreement is exempt from registration under the Securities Act, pursuant to the
exemption for transactions by an issuer not involving any public offering under Section 4(a)(2) of the Securities Act and Rule
506 of Regulation D promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_002"></A>RISK FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">A purchase of our shares of Common Stock
is an investment in our securities and involves a high degree of risk. You should carefully consider the risks and uncertainties
and all other information contained in or incorporated by reference in this prospectus, including the risks and uncertainties discussed
in our Annual Report on Form 10-K for the fiscal year ended December 31, 2014, as updated in our Quarterly Reports on Form 10-Q.
All of these risk factors are incorporated by reference herein in their entirety. If any of these risks actually occur, our business,
financial condition and results of operations would likely suffer. In that case, the market price of the Common Stock could decline,
and you may lose part or all of your investment in our company. Additional risks of which we are not presently aware or that we
currently believe are immaterial may also harm our business and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>We will need
to raise substantial additional capital in the future to fund our operations and we may be unable to raise such funds when needed
and on acceptable terms.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The extent to which
we utilize the Purchase Agreement with Aspire Capital as a source of funding will depend on a number of factors, including the
prevailing market price of our Common Stock, the volume of trading in our Common Stock and the extent to which we are able to secure
funds from other sources. The number of shares that we may sell to Aspire Capital under the Purchase Agreement on any given day
and during the term of the Purchase Agreement is limited. See &ldquo;Our Common Stock Purchase Agreement with Aspire Capital Fund,
LLC&rdquo; section of this prospectus for additional information. Additionally, we and Aspire Capital may not effect any sales
of shares of our Common Stock under the Purchase Agreement during the continuance of an event of default or on any trading day
that the closing sale price of our Common Stock is less than $0.10 per share. Even if we are able to access the full $25.0 million
under the Purchase Agreement, we will still need additional capital to fully implement our business, operating and development
plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">When we elect to raise
additional funds or additional funds are required, we may raise such funds from time to time through public or private equity offerings,
debt financings, corporate collaboration and licensing arrangements or other financing alternatives, as well as through sales of
Common Stock to Aspire Capital under the Purchase Agreement. Additional equity or debt financing or corporate collaboration and
licensing arrangements may not be available on acceptable terms, if at all. If we are unable to raise additional capital in sufficient
amounts or on terms acceptable to us, we will be prevented from pursuing acquisition, licensing, development and commercialization
efforts and our ability to generate revenues and achieve or sustain profitability will be substantially harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we raise additional
funds by issuing equity securities, our stockholders will experience dilution. Debt financing, if available, would result in increased
fixed payment obligations and may involve agreements that include covenants limiting or restricting our ability to take specific
actions, such as incurring additional debt, making capital expenditures or declaring dividends. Any debt financing or additional
equity that we raise may contain terms, such as liquidation and other preferences, which are not favorable to us or our stockholders.
If we raise additional funds through collaboration and licensing arrangements with third parties, it may be necessary to relinquish
valuable rights to our technologies, future revenue streams or product candidates or to grant licenses on terms that may not be
favorable to us. Should the financing we require to sustain our working capital needs be unavailable or prohibitively expensive
when we require it, our business, operating results, financial condition and prospects could be materially and adversely affected
and we may be unable to continue our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>The sale of our
Common Stock to Aspire Capital may cause substantial dilution to our existing stockholders and the sale of the shares of Common
Stock acquired by Aspire Capital could cause the price of our Common Stock to decline.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are registering
for sale the 6,086,207 shares that we may sell to Aspire Capital under the Purchase Agreement. It is anticipated that shares registered
in this offering will be sold over a period of up to approximately 30 months from the date of this prospectus. The number of shares
ultimately offered for sale by Aspire Capital under this prospectus is dependent upon the number of shares we elect to sell to
Aspire Capital under the Purchase Agreement. Depending upon market liquidity at the time, sales of shares of our common stock under
the Purchase Agreement may cause the trading price of our Common Stock to decline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Aspire Capital may
ultimately purchase all, some or none of the $25.0 million of Common Stock that is the subject of this prospectus. Aspire Capital
may sell all, some or none of our shares that it holds or comes to hold under the Purchase Agreement. Sales by Aspire Capital of
shares acquired pursuant to the Purchase Agreement under the registration statement, of which this prospectus is a part, may result
in dilution to the interests of other holders of our Common Stock. The sale of a substantial number of shares of our Common Stock
by Aspire Capital in this offering, or anticipation of such sales, could make it more difficult for us to sell equity or equity-related
securities in the future at a time and at a price that we might otherwise wish to effect sales. However, we have the right to control
the timing and amount of sales of our shares to Aspire Capital, and the Purchase Agreement may be terminated by us at any time
at our discretion without any penalty or cost to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Changes in regulations
and policies, including adverse coverage decisions by Medicare Administrative Contractors, or changes in payor mix is adversely
affecting, and could continue to adversely affect reimbursement for laboratory services and could have a material adverse impact
on our revenue and profitability.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Most of our services
are billed to a party other than the physician who ordered the test, including for example, Medicare and commercial insurance companies.
The majority of our pharmacogenomics tests have been billed to Medicare. Reimbursement levels for healthcare services are subject
to continuous and often unexpected changes in policies. Changes in governmental and third party reimbursement rates and policies
may result from statutory and regulatory changes, retroactive rate adjustments, administrative rulings, competitive bidding initiatives,
and other policy changes. Uncertainty also exists as to the coverage and reimbursement status of new services, including our pharmacogenomics
test and NAF test both of which are relatively new services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Government payors
and insurance companies have increased their efforts to control the cost, utilization, and delivery of healthcare services. For
example, at least yearly, Congress has considered and enacted changes in the Medicare fee schedule in conjunction with budgetary
legislation. Further reductions of reimbursement for Medicare services or changes in policy regarding coverage of tests may be
implemented from time to time. The payment amounts under the Medicare fee schedules are often used as a reference for the payment
amounts set by other third party payors. As a result, a reduction in Medicare reimbursement rates could result in a corresponding
reduction in the reimbursements we may receive from such third party payors. Changes in test coverage policies of other third
party payors may also occur. Such reimbursement and coverage changes in the past have resulted in reduced prices, added costs
and reduced accession volume, and have imposed more complex regulatory and administrative burdens. Further changes in federal,
state, and local third party payor laws, regulations, or policies may have a material adverse impact on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Adverse coverage
decisions by Medicare Administrative Contractors is having and could continue to have a material adverse impact on our revenue
and operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B>On
May 7, 2015, the Medicare Administrative Contractor covering the region in which the NRLBH operates issued a local coverage determination,
or LCD, that affects the Medicare reimbursement we expect to receive for our pharmacogenomics tests for tests performed on or after
the effective date of the LCD which was June 22, 2015. The LCD provides that Medicare reimbursement will be provided for pharmacogenomics
tests only for patients on a few specific drugs or for specific conditions at the reimbursement rate of $243 to $669 per test,
depending on the drug and condition, which is lower than our historic average reimbursement. Most of the pharmacogenomics tests
previously performed by the NRLBH have been for drugs and conditions for which Medicare reimbursement is not be available under
the new LCD. This new LCD has negatively impacted our revenue for the quarter ended September 30, 2015. For example, the LCD has
reduced the types of conditions and the pharmaceuticals for which Medicare will reimburse which we believe is indirectly causing
some commercial carriers to deny or limit coverage for some drugs or patients. This has negatively impacted the reimbursement rate
on our tests and the number of tests we performed in the third quarter 2015. Additionally, after the LCD went into effect, one
of our largest commercial payor has also denied coverage for a significant number of our pharmacogenomics tests which has adversely
impacted our third quarter 2015 revenue. The LCD could continue to significantly reduce number of tests submitted to the NRLBH,
the rate at which the NRLBH is reimbursed and could reduce the types of pharmaceuticals and conditions for which reimbursement
is available, which could have a significant adverse impact on our revenues and operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>If our stock
price does not appreciate above $1.00 per share, we may be delisted from NASDAQ which would adversely affect our stock price, liquidity
and our ability to raise capital.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On&nbsp;September 28,
2015,&nbsp;we received a letter from NASDAQ stating that the Company was not in compliance with NASDAQ Listing Rule 5550(a)(2),
because the Company's common stock failed to maintain a minimum closing bid price of&nbsp;$1.00&nbsp;per share for 30 consecutive
business days. We have until&nbsp;March 28, 2016&nbsp;to regain compliance. In the event we do not regain compliance by then, we
may be eligible for additional time if at that time we meet the continued listing requirement for market value of publicly held
shares and all other initial listing standards, with the exception of the bid price requirement, and provide written notice to
NASDAQ of our intention to cure the deficiency during the second compliance period, including by effecting a reverse stock split,
if necessary. The letter also states that the NASDAQ staff will provide written notification that we have regained compliance if
the bid price of our common stock closes at $1.00&nbsp;per share or more for a minimum of 10 consecutive business days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If our stock price
does not appreciate above $1.00 per share we may be delisted from NASDAQ which could adversely affect our stock price, liquidity
and our ability to raise funding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>If we are not
able to protect our proprietary technology, others could compete against us more directly, which would harm our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our commercial success
will depend, in part, on our ability to obtain additional patents and licenses and protect our existing patent position, both in
the United States and in other countries, for devices, kits, diagnostics tests, Therapeutics and related technologies, processes,
methods, compositions and other inventions that we believe are patentable. Our ability to preserve our trade secrets and other
intellectual property is also important to our long-term success. If we do not adequately protect our intellectual property, competitors
may be able to use our technologies and erode or negate any competitive advantage we may have, which could harm our business and
ability to maintain profitability. Patents may also issue to third parties which could interfere with our ability to bring our
molecular diagnostic tests or therapeutics to market. The laws of some foreign countries do not protect our proprietary rights
to the same extent as U.S. laws, and we may encounter significant problems in protecting our proprietary rights in these countries.
The patent positions of diagnostic companies and pharmaceutical and biotechnology companies, including our patent position, are
generally highly uncertain and particularly after the Supreme Court decisions, Mayo Collaborative Services v. Prometheus Laboratories
, 132 S. Ct. 1289 (2012), Association for Molecular Pathology v. Myriad , 133 S. Ct. 2107 (2013), and Alice Corp. v. CLS Bank Int&rsquo;l
, 134 S. Ct. 2347 (2014), and involve complex legal and factual questions, and, therefore, any patents issued to us may be challenged,
deemed unenforceable, invalidated or circumvented. We will be able to protect our proprietary rights from unauthorized use by third
parties only to the extent that our proprietary technologies and any future tests are covered by valid and enforceable patents
or are effectively maintained as trade secrets. Our patent applications may never issue as patents, and the claims of any issued
patents may not afford meaningful protection for our technology or tests. In addition, any patents issued to us or our licensors
may be challenged, and subsequently narrowed, invalidated or circumvented.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">The degree of future protection for our proprietary rights is uncertain, and we cannot ensure that:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">we or our licensors were the first to make the inventions covered by each of our patent applications;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">we or our licensors were the first to file patent applications for these inventions;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">others will not independently develop similar or alternative technologies or duplicate any of our
technologies;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">any of our or our licensors&rsquo; patent applications will result in issued patents;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">any of our or our licensors&rsquo; patents will be valid or enforceable;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">any patents issued to us or our licensors and collaborators will provide a basis for commercially
viable tests and/or Therapeutics, will provide us with any competitive advantages or will not be challenged by third parties;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">we will develop additional proprietary technologies or tests that are patentable;</TD></TR>                                                                                                                                                                                                                                          <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Symbol; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"></TD><TD STYLE="text-align: justify"></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the patents of others will not have an adverse effect on our business; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our patents or patents that we license from others will survive legal challenges, and remain valid
and enforceable.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If a third party files
a patent application with claims to a biomarker or a drug we have discovered or developed, a derivation proceeding may be initiated
regarding competing patent applications. If an derivation proceeding is initiated, we may not prevail in the derivation proceeding.
If the other party prevails in the derivation proceeding, we may be precluded from commercializing services or tests based on the
biomarker or the drug, or may be required to seek a license. A license may not be available to us on commercially acceptable terms,
if at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also rely upon unpatented
proprietary technologies. Although we require employees, consultants and collaborators to sign confidentiality agreements, we may
not be able to adequately protect our rights in such unpatented proprietary technologies, which could have a material adverse effect
on our business. For example, others may independently develop substantially equivalent proprietary information or techniques or
otherwise gain access to our proprietary technologies or disclose our technologies to our competitors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>If we were sued
for patent infringement by third parties, we might incur significant costs and delays in test or drug introduction.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our tests and drug
candidates may also conflict with patents that have been or may be granted to others. Our industry includes many organizations
that have or are seeking to discern biomarkers and develop genomic, proteomic and other technologies and also develop drugs. To
the extent any patents are issued or have been issued to those organizations, the risk increases that the sale of our molecular
diagnostic and companion diagnostic tests, and drugs under development may give rise to claims of patent infringement. Others may
have filed and in the future are likely to file patent applications covering biomarkers that are similar or identical to our tests
and/or drugs that are similar to our drugs. Any of these patent applications may have priority over our patent applications and
these entities or persons could bring legal proceedings against us seeking damages or seeking to enjoin us from testing or marketing
our tests. Patent litigation is costly, and even if we prevail, the cost of such litigation could have a material adverse effect
on us. If the other parties in any such actions are successful, in addition to any liability for damages, we could be required
to cease the infringing activity or obtain a license. Any license required may not be available to us on commercially acceptable
terms, if at all. Our failure to obtain a license to any technology that we may require to commercialize our tests could have a
material adverse effect on our business. We believe that there may be significant litigation in the industry regarding patent and
other intellectual property rights. If we become involved in this litigation, it could consume a substantial portion of our managerial
and financial resources.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>If we fail to
comply with our obligations under license or technology agreements with third parties, we could lose license rights that are critical
to our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We license intellectual
property that is critical to our business, including licenses underlying the technology in our molecular diagnostic and pharmaceutical
and clinical services and therapeutics and in the future we may enter into additional agreements that provide us with licenses
to valuable intellectual property or technology. These licenses impose various royalty payments, milestones, and other obligations
on us. If we fail to comply with any of these obligations, the licensor may have the right to terminate the license. Termination
by the licensor would cause us to lose valuable rights, and could prevent us from distributing our current tests and/or drugs,
or inhibit our ability to commercialize future test and/or therapeutics candidates. Our business would suffer if any current or
future licenses terminate, if the licensors fail to abide by the terms of the license, if the licensors fail to prevent infringement
by third parties, if the licensed patents or other rights are found to be invalid or unenforceable, or if we are unable to enter
into necessary licenses on acceptable terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_003"></A>USE OF PROCEEDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus relates
to shares of our Common Stock that may be offered and sold from time to time by Aspire Capital. We will not receive any proceeds
upon the sale of shares by Aspire Capital. However, we may receive proceeds up to $25.0 million under the Purchase Agreement with
Aspire Capital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The proceeds received from the sale of the shares under the
Purchase Agreement will be used for working capital and general corporate purposes. However, we cannot guarantee that we will receive
any proceeds in connection with the Purchase Agreement because we may be unable or choose not to issue and sell any securities
pursuant to the Purchase Agreement. This anticipated use of net proceeds from the sale of our Common Stock to Aspire Capital under
the Purchase Agreement represents our intentions based upon our current plans and business conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_004"></A>DIVIDEND POLICY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have not declared
any dividends and do not anticipate that we will declare dividends in the foreseeable future; rather, we intend to retain any future
earnings for the development of the business. Payment of future cash dividends, if any, will be at the discretion of our Board
of Directors after taking into account various factors, including our financial condition, operating results, current and anticipated
cash needs, outstanding indebtedness and plans for expansion and restrictions imposed by lenders, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_005"></A>SELLING STOCKHOLDER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Selling Stockholder
may from time to time offer and sell any or all of the shares of our Common Stock set forth below pursuant to this prospectus.
When we refer to the &ldquo;Selling Stockholder&rdquo; in this prospectus, we mean the entity listed in the table below, and its
respective pledgees, donees, permitted transferees, assignees, successors and others who later come to hold any of the Selling
Stockholder&rsquo;s interests in shares of our Common Stock other than through a public sale.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table
sets forth, as of the date of this prospectus, the name of the Selling Stockholder for whom we are registering shares for sale
to the public, the number of shares of Common Stock beneficially owned by the Selling Stockholder prior to this offering, the total
number of shares of Common Stock that the Selling Stockholder may offer pursuant to this prospectus and the number of shares of
Common Stock that the Selling Stockholder will beneficially own after this offering. Except as noted below, the Selling Stockholder
does not have, or within the past three years has not had, any material relationship with us or any of our predecessors or affiliates
and the Selling Stockholder is not or was not affiliated with registered broker-dealers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based on the information provided to us
by the Selling Stockholder, assuming that the Selling Stockholder sells all of the shares of our Common Stock beneficially owned
by it that have been registered by us and does not acquire any additional shares during the offering, the Selling Stockholder will
not own any shares other than those appearing in the column entitled &ldquo;Beneficial Ownership After This Offering.&rdquo; We
cannot advise you as to whether the Selling Stockholder will in fact sell any or all of such shares of Common Stock. In addition,
the Selling Stockholder may have sold, transferred or otherwise disposed of, or may sell, transfer or otherwise dispose of, at
any time and from time to time, the shares of our Common Stock in transactions exempt from the registration requirements of the
Securities Act after the date on which it provided the information set forth in the table below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Selling Stockholder</B></FONT></TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Shares</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Beneficially</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Owned&nbsp;Before</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Offering</B></FONT></TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Percentage&nbsp;of</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Outstanding&nbsp;Shares</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Beneficially Owned</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Before Offering</B></FONT></TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Shares to be</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Sold in the</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Offering</B></FONT></TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Shares</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Beneficially</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Owned After</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Offering (1)</B></FONT></TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Percentage of</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Outstanding</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Shares</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Beneficially</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Owned After</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Offering</B></FONT></TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 35%"><FONT STYLE="font-size: 10pt">Aspire Capital Fund, LLC (2)</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">1,520,833</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">4.995</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">6,086,207</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">1,520,833</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">4.160% </FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">(5)</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 3%">(1)</TD>
    <TD STYLE="width: 96%; text-align: justify">Assumes the sale of all shares of Common Stock registered pursuant to this prospectus, although the Selling Stockholder is under no obligation known to us to sell any shares at this time.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-indent: -0.2in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 3%">(2)</TD>
    <TD STYLE="width: 96%; text-align: justify">Aspire Capital Partners LLC (&ldquo;Aspire Partners&rdquo;) is the Managing Member of Aspire Capital Fund LLC (&ldquo;Aspire Capital&rdquo;). SGM Holdings Corp (&ldquo;SGM&rdquo;) is the Managing Member of Aspire Partners. Mr. Steven G. Martin (&ldquo;Mr. Martin&rdquo;) is the president and sole shareholder of SGM, as well as a principal of Aspire Partners. Mr. Erik J. Brown (&ldquo;Mr. Brown&rdquo;) is the president and sole shareholder of Red Cedar Capital Corp (&ldquo;Red Cedar&rdquo;), which is a principal of Aspire Partners. Mr. Christos Komissopoulos (&ldquo;Mr. Komissopoulos&rdquo;) is president and sole shareholder of Chrisko Investors Inc. (&ldquo;Chrisko&rdquo;), which is a principal of Aspire Partners. Each of Aspire Partners, SGM, Red Cedar, Chrisko, Mr. Martin, Mr. Brown, and Mr. Komissopoulos may be deemed to be a beneficial owner of common stock held by Aspire Capital. Each of Aspire Partners, SGM, Red Cedar, Chrisko, Mr. Martin, Mr. Brown, and Mr. Komissopoulos disclaims beneficial ownership of the Common Stock held by Aspire Capital, except to extent of their pecuniary interest therein. Aspire Capital is not a licensed broker dealer nor is any of its affiliate a licensed broker dealer.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-indent: -0.2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-indent: -0.2in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 3%; font-size: 10pt"><FONT STYLE="font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="width: 96%; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">As of the date hereof, 1,520,833 shares of our common stock are owned by Aspire Capital, consisting of 1,520,833 shares previously purchased by Aspire Capital. We may elect in our sole discretion to sell to Aspire Capital up to an additional 6,086,207 shares under the Purchase Agreement and included in this prospectus but Aspire Capital does not presently beneficially own those shares as determined in accordance with the rules of the SEC.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-indent: -0.2in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-indent: -0.2in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-indent: -0.2in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 3%">(4)</TD>
    <TD STYLE="width: 96%">Amount equals shares beneficially owned before the offering and assumes no additional sales of the remaining 1,520,833 shares.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(5)</TD>
    <TD>Based on 30,446,260 shares of Common Stock outstanding as of November 19, 2015.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_006"></A>THE ASPIRE CAPITAL TRANSACTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>General</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 11, 2015,
we entered into the Purchase Agreement which provides that, upon the terms and subject to the conditions and limitations set forth
therein, Aspire Capital is committed to purchase up to an aggregate of $25.0 million of our shares of Common Stock over the term
of the Purchase Agreement. Concurrently with entering into the Purchase Agreement, we also entered into the Registration Rights
Agreement, in which we agreed to file one or more registration statements as permissible and necessary to register under the Securities
Act, the sale of the shares of our Common Stock that have been and may be issued to Aspire Capital under the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of November
11, 2015, there were 30,446,260 shares of our Common Stock outstanding (25,667,728 shares held by non-affiliates), excluding
the 6,086,207 shares offered that have not been issued but may become issuable to Aspire Capital pursuant to the Purchase
Agreement. If all of the 6,086,207 shares of our Common Stock offered hereby were issued and outstanding as of the date
thereof, such shares would represent 19.99% of the total Common Stock outstanding or 23.71% of the non-affiliate shares of
Common Stock outstanding as of the date thereof. The number of shares of our Common Stock ultimately offered for sale by
Aspire Capital is dependent upon the number of shares purchased by Aspire Capital under the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of November 19,
2015, there were 30,446,260 shares of our Common Stock outstanding (25,667,728 shares held by non-affiliates), excluding the 6,086,207
shares offered that have not been issued but may become issuable to Aspire Capital pursuant to the Purchase Agreement. The number
of shares of our Common Stock ultimately offered for sale by Aspire Capital is dependent upon the number of shares purchased by
Aspire Capital under the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Purchase
Agreement and the Registration Rights Agreement, we are registering 6,086,207 shares of our Common Stock under the Securities Act,
which we may issue to Aspire Capital after this registration statement is declared effective under the Securities Act. Under the
Purchase Agreement, we have the right but not the obligation to issue more than the 6,086,207 shares of Common Stock included in
this prospectus to Aspire Capital. As of the date hereof, we do not have any plans or intent to issue to Aspire Capital any shares
of Common Stock in addition to the 6,086,207 shares of Common Stock offered hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">After the Securities
and Exchange Commission has declared effective the registration statement of which this prospectus is a part, on any trading day
on which the closing sale price of our Common Stock is not less than $0.10 per share, we have the right, in our sole discretion,
to present Aspire Capital with a Purchase Notice, directing Aspire Capital (as principal) to purchase up to 150,000 shares of our
Common Stock per business day, up to $25.0 million of our Common Stock in the aggregate at a Purchase Price calculated by reference
to the prevailing market price of our Common Stock over the preceding 12-business day period (as more specifically described below).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, on any
date on which we submit a Purchase Notice to Aspire Capital for 150,000 shares of our Common Stock and our stock price is not less
than $0.50 per share, we also have the right, in our sole discretion, to present Aspire Capital with a VWAP Purchase Notice directing
Aspire Capital to purchase an amount of stock equal to up to 30% of the aggregate shares of the Company&rsquo;s common stock traded
on the NASDAQ on the next trading day, subject to the VWAP Purchase Share Volume Maximum and the VWAP Minimum Price Threshold.
The VWAP Purchase Price is calculated by reference to the prevailing market price of our Common Stock (as more specifically described
below).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Purchase Agreement
provides that the Company and Aspire Capital shall not effect any sales under the Purchase Agreement on any purchase date where
the closing sale price of our Common Stock is less than $0.10. There are no trading volume requirements or restrictions under the
Purchase Agreement, and we will control the timing and amount of any sales of our Common Stock to Aspire Capital. Aspire Capital
has no right to require any sales by us, but is obligated to make purchases from us as we direct in accordance with the Purchase
Agreement. There are no limitations on use of proceeds, financial or business covenants, restrictions on future fundings, rights
of first refusal, participation rights, penalties or liquidated damages in the Purchase Agreement. Aspire Capital may not assign
its rights or obligations under the Purchase Agreement. The Purchase Agreement may be terminated by us at any time, at our discretion,
without any penalty or cost to us. The Purchase Agreement provides that on the date of its execution, the certain Purchase Agreement,
dated as of May 26, 2015, by and between the Company and Aspire Capital, was terminated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Purchase of shares under the Purchase Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Purchase
Agreement, on any trading day selected by us on which the closing sale price of our Common Stock exceeds $0.10 per share, we may
direct Aspire Capital to purchase up to 150,000 shares of our Common Stock per trading day. The Purchase Price of such shares is
equal to the lesser of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the lowest sale price of our Common Stock on the purchase date; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the arithmetic average of the three lowest closing sale prices for our Common Stock during the
twelve consecutive trading days ending on the trading day immediately preceding the purchase date.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, on any
date on which we submit a Purchase Notice to Aspire Capital for purchase of 150,000 shares and our stock price is not less than
$0.50 per share, we also have the right to direct Aspire Capital to purchase an amount of stock equal to up to 30% of the aggregate
shares of the our Common Stock traded on the NASDAQ on the next trading day, subject to the VWAP Purchase Share Volume Maximum
and the VWAP Minimum Price Threshold, which is equal to the greater of (a) 80% of the closing price of our Common Stock on the
business day immediately preceding the VWAP Purchase Date or (b) such higher price as set forth by the Company in the VWAP Purchase
Notice. The VWAP Purchase Price of such shares is the lower of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the closing sale price on the VWAP Purchase Date; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">95% of the volume-weighted average price for our Common Stock traded on the NASDAQ :</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">on the VWAP Purchase Date, if the aggregate shares to be purchased on that date have not exceeded
the VWAP Purchase Share Volume Maximum or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">during that portion of the VWAP Purchase Date until such time as the sooner to occur of (i) the
time at which the aggregate shares traded on the NASDAQ exceed the VWAP Purchase Share Volume Maximum or (ii) the time at which
the sale price of our Common Stock falls below the VWAP Minimum Price Threshold.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The purchase price
will be adjusted for any reorganization, recapitalization, non-cash dividend, stock split, or other similar transaction occurring
during the trading day(s) used to compute the purchase price. We may deliver multiple Purchase Notices and VWAP Purchase Notices
to Aspire Capital from time to time during the term of the Purchase Agreement, so long as the most recent purchase has been completed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Minimum Share Price</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Purchase
Agreement, the Company and Aspire Capital may not effect any sales of shares of our Common Stock on any trading day that the closing
sale price of our Common Stock is less than $0.10 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Compliance with the NASDAQ Capital Market Rules</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Purchase Agreement
provides that the number of shares that may be sold pursuant to the Purchase Agreement shall be limited to 6,086,207, or the Exchange
Cap, which represents 19.99% of our outstanding shares as of November 11, 2015, unless shareholder approval or an exception pursuant
to the rules of the NASDAQ Capital Market is obtained to issue more than 19.99%, to be in compliance with the applicable listing
maintenance rules of the NASDAQ Capital Market. We are not required or permitted to issue any shares of Common Stock under the
Purchase Agreement if such issuance would breach our obligations under the rules or regulations of the NASDAQ Capital Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Beneficial Ownership Limitation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Purchase
Agreement, we and Aspire Capital may not effect any sales of shares of our Common Stock if such shares proposed to be issued and
sold, when aggregated with all other shares of our Common Stock beneficially owned by Aspire Capital and its affiliates, would
result in the beneficial ownership by Aspire Capital and its affiliates of more than 19.99% of our then issued and outstanding
shares of Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Events of Default</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Generally, Aspire Capital may terminate
the Purchase Agreement upon the occurrence of any of the following events of default:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the effectiveness of any registration statement that is required to be maintained effective pursuant
to the terms of the Registration Rights Agreement between us and Aspire Capital lapses for any reason (including, without limitation,
the issuance of a stop order) or is unavailable to Aspire Capital for sale of our shares of Common Stock, and such lapse or unavailability
continues for a period of ten consecutive business days or for more than an aggregate of thirty business days in any 365-day period,
which is not in connection with a post-effective amendment to any such registration statement; in connection with any post-effective
amendment to such registration statement that is required to be declared effective by the Securities and Exchange Commission (the
&ldquo;<B><I>SEC</I></B>&rdquo;) such lapse or unavailability may continue for a period of no more than 40 consecutive business
days;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the suspension from trading or failure of our Common Stock to be listed on our principal market
for a period of ten consecutive business days;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the delisting of our Common Stock from the NASDAQ, provided
however, that in the event our Common Stock is not immediately thereafter listed and traded on the New York Stock Exchange, the
NYSE MKT, the Nasdaq Global Select Market, the Nasdaq Global Market, the Over-The-Counter Bulletin Board interdealer quotation
system or either one of the OTCQB or the OTCQX market places of the OTC Markets Group, Inc.;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our transfer agent&rsquo;s failure to issue to Aspire Capital shares of our Common Stock which
Aspire Capital is entitled to receive under the Purchase Agreement within five business days after an applicable purchase date;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">any breach by us of the representations or warranties or
covenants contained in the Purchase Agreement or any related agreements which could have a material adverse effect on us, subject
to a cure period of five business days;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">if we become insolvent or are generally unable to pay our debts as they become due; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">any participation or threatened participation in insolvency or bankruptcy proceedings by or against
us.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Minimum Share Price</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Purchase
Agreement, we and Aspire Capital may not effect any sales of shares of our common stock under the Purchase Agreement on any trading
day that the closing sale price of our common stock is less than $0.10 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Our Termination Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Purchase Agreement
may be terminated by us at any time, at our discretion, without any cost to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>No Short-Selling or Hedging by Aspire
Capital</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Aspire Capital has
agreed that neither it nor any of its agents, representatives and affiliates shall engage in any direct or indirect short-selling
or hedging, which establishes a net short position with respect to our Common Stock during any time prior to the termination of
the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Effect of Performance of the Purchase
Agreement on Our Stockholders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Purchase Agreement
does not limit the ability of Aspire Capital to sell any or all of the 6,086,207 shares registered in this offering. It is anticipated
that shares registered in this offering will be sold over a period of up to approximately 30 months from the date of this prospectus.
The sale by Aspire Capital of a significant amount of shares registered in this offering at any given time could cause the market
price of our Common Stock to decline and/or to be highly volatile. Aspire Capital may ultimately purchase all, some or none of
the 6,086,207 shares of Common Stock not yet issued but registered in this offering. After it has acquired such shares, it may
sell all, some or none of such shares. Therefore, sales to Aspire Capital by us pursuant to the Purchase Agreement also may result
in substantial dilution to the interests of other holders of our Common Stock. However, we have the right to control the timing
and amount of any sales of our shares to Aspire Capital and the Purchase Agreement may be terminated by us at any time at our discretion
without any penalty or cost to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Amount of Potential Proceeds to be Received under the Purchase
Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with
entering into the Purchase Agreement, we authorized the sale to Aspire Capital of up to $25.0 million of our shares of Common Stock.
However, we estimate that we will sell no more than 6,086,207 shares to Aspire Capital under the Purchase Agreement, all of which
are included in this offering. Subject to any required approval by our Board of Directors, we have the right but not the obligation
to issue more than the 6,086,207 shares included in this prospectus to Aspire Capital under the Purchase Agreement. In the event
we elect to issue more than 6,086,207 shares under the Purchase Agreement, we will be required to file a new registration statement
and have it declared effective by the SEC. The number of shares ultimately offered for sale by Aspire Capital in this offering
is dependent upon the number of shares purchased by Aspire Capital under the Purchase Agreement. The following table sets forth
the number and percentage of outstanding shares to be held by Aspire Capital after giving effect to the sale of shares of Common
Stock issued to Aspire Capital at varying purchase prices:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid">Assumed&nbsp;Average<BR> Purchase&nbsp;Price</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Proceeds&nbsp;from&nbsp;the&nbsp;Sale<BR> of&nbsp;Shares&nbsp;to&nbsp;Aspire<BR> Capital&nbsp;Under&nbsp;the<BR> Purchase&nbsp;Agreement<BR> Registered&nbsp;in&nbsp;this<BR> Offering</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid">Number&nbsp;of&nbsp;Shares&nbsp;to&nbsp;be<BR> Issued&nbsp;in&nbsp;this&nbsp;Offering<BR> at&nbsp;the&nbsp;Assumed&nbsp;Average<BR> Purchase&nbsp;Price</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Percentage&nbsp;of&nbsp;Outstanding<BR> Shares&nbsp;After&nbsp;Giving&nbsp;Effect<BR> to&nbsp;the&nbsp;Purchased&nbsp;Shares<BR> Issued&nbsp;to&nbsp;Aspire&nbsp;Capital&nbsp;(1)</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 23%; text-align: right">0.10</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 22%; text-align: right">608,620.70</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 22%; text-align: right">6,086,207</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 22%; text-align: right">16.66</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.25</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,521,551.75</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,086,207</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16.66</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.50</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3,043,103.50</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,086,207</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16.66</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">6,086,207.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,086,207</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16.66</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">12,172,414.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,086,207</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16.66</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">18,258,621.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,086,207</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16.66</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">24,344,828.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,086,207</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16.66</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">6.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">25,000,000.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,166,666</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12.04</TD><TD STYLE="text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%">(1)</TD>
    <TD STYLE="width: 94%; text-align: justify">The denominator is based on 30,446,260 shares outstanding as of November 19, 2015, which includes the number of shares set forth in the adjacent column which we would have sold to Aspire Capital at the corresponding assumed purchase price set forth in the adjacent column. The numerator is based on the number of shares which we may issue to Aspire Capital under the Purchase Agreement (that are the subject of this offering) at the corresponding assumed purchase price set forth in the adjacent column.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">DILUTION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The sale of our common
stock to Aspire Capital pursuant to the Purchase Agreement will have a dilutive impact on our stockholders. As a result, our net
income per share, if any, would decrease in future periods and the market price of our Common Stock could decline. In addition,
the lower our stock price is at the time we exercise our right to sell shares to Aspire Capital, the more shares of our Common
Stock we will have to issue to Aspire Capital pursuant to the Purchase Agreement and our existing stockholders would experience
greater dilution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our net tangible book
value as of September 30, 2015 was approximately $7.3 million, or $0.24 per share. Net tangible book value per share is determined
by dividing our total tangible assets, less total liabilities, by the number of shares of our common stock outstanding as of September
30, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">After giving effect to the sale in this offering of 6,086,207 shares of common stock at an assumed average sale price
of $0.44 per share (based on the lowest sales price of our common stock as of November 25, 2015), our pro forma as adjusted net
tangible book value as of September 30, 2015 would have been approximately $10.0 million, or $0.27 per share of Common Stock.
This represents an immediate increase in pro forma as adjusted net tangible book value of $0.03 per share to our existing stockholders
and an immediate dilution of $0.17 per share to our new stockholders.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_007"></A>PLAN OF DISTRIBUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Common Stock offered
by this prospectus is being offered by Aspire Capital, the Selling Stockholder. The Common Stock may be sold or distributed from
time to time by the Selling Stockholder directly to one or more purchasers or through brokers, dealers, or underwriters who may
act solely as agents at market prices prevailing at the time of sale, at prices related to the prevailing market prices, at negotiated
prices, or at fixed prices, which may be changed. The sale of the Common Stock offered by this prospectus may be effected by one
or more of the following methods:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">ordinary brokers&rsquo; transactions;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">transactions involving cross or block trades;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">through brokers, dealers, or underwriters who may act solely as agents;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">&ldquo;at the market&rdquo; into an existing market for the common stock;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">in other ways not involving market makers or established business markets, including direct sales
to purchasers or sales effected through agents;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">in privately negotiated transactions; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">any combination of the foregoing.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In order to comply
with the securities laws of certain states, if applicable, the shares may be sold only through registered or licensed brokers or
dealers. In addition, in certain states, the shares may not be sold unless they have been registered or qualified for sale in the
state or an exemption from the registration or qualification requirement is available and complied with.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Selling Stockholder
may also sell shares of Common Stock under Rule 144 promulgated under the Securities Act, if available, rather than under this
prospectus. In addition, the Selling Stockholder may transfer the shares of our Common Stock by other means not described in this
prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Brokers, dealers, underwriters,
or agents participating in the distribution of the shares as agents may receive compensation in the form of commissions, discounts,
or concessions from the selling stockholder and/or purchasers of the common stock for whom the broker-dealers may act as agent.
Aspire Capital has informed us that each such broker-dealer will receive commissions from Aspire Capital which will not exceed
customary brokerage commissions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Aspire Capital is an
&ldquo;underwriter&rdquo; within the meaning of the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Neither we nor Aspire
Capital can presently estimate the amount of compensation that any agent will receive. We know of no existing arrangements between
Aspire Capital, any other shareholder, broker, dealer, underwriter, or agent relating to the sale or distribution of the shares
offered by this prospectus. At the time a particular offer of shares is made, a prospectus supplement, if required, will be distributed
that will set forth the names of any agents, underwriters, or dealers and any compensation from the selling stockholder, and any
other required information. Pursuant to a requirement of the Financial Industry Regulatory Authority, or FINRA, the maximum commission
or discount and other compensation to be received by any FINRA member or independent broker-dealer shall not be greater than eight
percent (8%) of the gross proceeds received by us for the sale of any securities being registered pursuant to Rule 415 under the
Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will pay all of
the expenses incident to the registration, offering, and sale of the shares to the public other than commissions or discounts of
underwriters, broker-dealers, or agents. We have agreed to indemnify Aspire Capital and certain other persons against certain liabilities
in connection with the offering of shares of our Common Stock offered hereby, including liabilities arising under the Securities
Act or, if such indemnity is unavailable, to contribute amounts required to be paid in respect of such liabilities. Aspire Capital
has agreed to indemnify us against liabilities under the Securities Act that may arise from certain written information furnished
to us by Aspire Capital specifically for use in this prospectus or, if such indemnity is unavailable, to contribute amounts required
to be paid in respect of such liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Insofar as indemnification
for liabilities arising under the Securities Act may be permitted to our directors, officers, and controlling persons, we have
been advised that in the opinion of the SEC this indemnification is against public policy as expressed in the Securities Act and
is therefore, unenforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Aspire Capital and
its affiliates have agreed not to engage in any direct or indirect short selling or hedging of our Common Stock during the term
of the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have advised Aspire
Capital that while it is engaged in a distribution of the shares included in this prospectus it is required to comply with Regulation
M promulgated under the Securities Exchange Act of 1934, as amended. With certain exceptions, Regulation M precludes the Selling
Stockholder, any affiliated purchasers, and any broker-dealer or other person who participates in the distribution from bidding
for or purchasing, or attempting to induce any person to bid for or purchase any security which is the subject of the distribution
until the entire distribution is complete. Regulation M also prohibits any bids or purchases made in order to stabilize the price
of a security in connection with the distribution of that security. All of the foregoing may affect the marketability of the shares
offered hereby this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may suspend the
sale of shares by Aspire Capital pursuant to this prospectus for certain periods of time for certain reasons, including if the
prospectus is required to be supplemented or amended to include additional material information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This offering will
terminate on the date that all shares offered by this prospectus have been sold by Aspire Capital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><A NAME="a_008"></A><B>DESCRIPTION
OF SECURITIES TO BE REGISTERED</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our authorized capital
stock consists of 75,000,000 shares of Common Stock, $0.001 par value per share, and 10,000,000 shares of preferred stock, $0.001
par value per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Holders of Common Stock
are entitled to receive ratably dividends out of funds legally available, if and when declared from time to time by our Board of
Directors. We have never paid any cash dividends on our Common Stock and our Board of Directors does not anticipate that we will
pay cash dividends in the foreseeable future. The future payment of dividends, if any, on our Common Stock is within the discretion
of the Board of Directors and will depend upon earnings, capital requirements, financial condition and other relevant factors.
Holders of Common Stock are entitled to one vote for each share held on each matter to be voted on by stockholders. There is no
cumulative voting in the election of directors. In the event of liquidation, dissolution or winding up of the affairs of us, holders
of Common Stock are to share in all assets remaining after the payment of liabilities and any preferential distributions payable
to preferred stockholders, if any. The holders of Common Stock have no preemptive or conversion rights and are not subject to further
calls or assessments. There are no redemption or sinking fund provisions applicable to the Common Stock. The rights of the holders
of the Common Stock are subject to any rights that may be fixed for holders of preferred stock, if any. All of the outstanding
shares of Common Stock are fully paid and non-assessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Certificate of Incorporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under our certificate
of incorporation, as amended, our Board of Directors, without further action by our stockholders, currently has the authority to
issue up to 10,000,000 shares of preferred stock and to fix the rights (including voting rights), preferences and privileges of
these &ldquo;blank check&rdquo; preferred shares. Such preferred stock may have rights, including economic rights, senior to our
Common Stock. As a result, the issuance of the preferred stock could have a material adverse effect on the price of our Common
Stock and could make it more difficult for a third party to acquire a majority of our outstanding Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Anti-Takeover Devices</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our certificate of
incorporation and bylaws include a number of provisions that may have the effect of delaying, deferring or preventing another party
from acquiring control of us and encouraging persons considering unsolicited tender offers or other unilateral takeover proposals
to negotiate with our Board of Directors rather than pursue non-negotiated takeover attempts. These provisions include the items
described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Board Composition
and Filling Vacancies.</I> In accordance with our certificate of incorporation, our Board of Directors is divided into three classes
serving staggered three-year terms, with one class being elected each year. Our certificate of incorporation also provides that
directors may only be removed from office for cause and only by the affirmative vote of holders of 75% or more of the outstanding
shares of capital stock then entitled to vote at an election of directors. Furthermore, any vacancy on our Board of Directors,
however occurring, including any vacancy resulting from an increase in the size of the board, may only be filled by the affirmative
vote of a majority of our directors then in office even if less than a quorum. The classification of directors, together with the
limitations on removal of directors and treatment of vacancies, has the effect of making it more difficult for stockholders to
change the composition of our Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Undesignated Preferred
Stock.</I> Our certificate of incorporation authorizes &ldquo;blank-check&rdquo; preferred stock, which means that our Board of
Directors has the authority to designate one or more series of preferred stock without stockholder approval. These series of preferred
stock may have superior rights, preferences and privileges over our Common Stock, including dividend rights, voting rights and
liquidation preferences. The ability of our Board of Directors to issue shares of our preferred stock without stockholder approval
could deter takeover offers and make it more difficult or costly for a third party to acquire us without the consent of our Board
of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Section 203 of the
Delaware General Corporation Law.</I> In addition, our certificate of incorporation does not opt out of Section 203 of the Delaware
General Corporation Law, which protects a corporation against an unapproved takeover by prohibiting a company from engaging in
any business combination with any interested stockholder (defined as a stockholder owning more than 15% of the outstanding shares)
for a period of three years from the time such stockholder became a 15% holder unless approved by our Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Stockholder Rights
Agreement. </I>On May 19, 2014, the Company adopted a stockholder rights agreement which provides that all stockholders of record
on May 26, 2014 received a non-taxable distribution of one preferred stock purchase right for each share of our Common Stock held
by such stockholder. Each right is attached to and trades with the associated share of Common Stock. The rights will become exercisable
only if one of the following occurs: (1)&nbsp;a person becomes an &ldquo;Acquiring Person&rdquo; by acquiring beneficial ownership
of 15% or more of our Common Stock (or, in the case of a person who beneficially owned 15% or more of our Common Stock on the date
the stockholder rights agreement was executed, by acquiring beneficial ownership of additional shares representing 2.0% of our
Common Stock then outstanding (excluding compensatory arrangements)), or (2)&nbsp;a person commences a tender offer that, if consummated,
would result in such person becoming an Acquiring Person. If a person becomes an Acquiring Person, each right will entitle the
holder, other than the Acquiring Person and certain related parties, to purchase a number of shares of our Common Stock with a
market value that equals twice the exercise price of the right. The initial exercise price of each right is $15.00, so each holder
(other than the Acquiring Person and certain related parties) exercising a right would be entitled to receive $30.00 worth of our
Common Stock. If the Company is acquired in a merger or similar business combination transaction at any time after a person has
become an Acquiring Person, each holder of a right (other than the Acquiring Person and certain related parties) will be entitled
to purchase a similar amount of stock of the acquiring entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Transfer Agent and Registrar</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have appointed VStock
Transfer, LLC, 18 Lafayette Place, Woodmere, New York 11598 (Telephone: (212) 828-8436; Facsimile (646) 536-3179) as our transfer
agent and registrar.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Listing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our Common Stock is listed on the NASDAQ
Capital Market under the symbol &ldquo;ATOS&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_009"></A>DISCLOSURE OF COMMISSION POSITION ON
INDEMNIFICATION FOR SECURITIES ACT LIABILITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Insofar as indemnification
for liabilities arising under the Securities Act may be permitted to directors, officers, and controlling persons of the registrant
pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange
Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="a_010"></A>LEGAL MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Certain legal matters relating to the validity
of the Common Stock offered by this prospectus will be passed upon for us by Gibson, Dunn &amp; Crutcher, LLP, San Francisco, California.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="a_011"></A>EXPERTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The consolidated financial
statements as of December 31, 2014 and for the year then ended incorporated by reference in this Prospectus have been so included
in reliance on the report of BDO USA, LLP, an independent registered public accounting firm (the report on the consolidated financial
statements contains an explanatory paragraph regarding the Company's ability to continue as a going concern) which is incorporated
by reference in the Prospectus, given on the authority of said firm as experts in auditing and accounting. KCCW Accountancy Corp.,
an independent PCAOB registered public accounting firm, has audited the Company&rsquo;s consolidated balance sheets as of December
31, 2013 and the related consolidated statements of operations, stockholders&rsquo; equity, and cash flows for the year then ended,
which are incorporated by reference in this prospectus. The consolidated financial statements are included in reliance on the report
of KCCW Accountancy Corp., given their authority as experts in accounting and auditing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_012"></A>WHERE YOU CAN FIND ADDITIONAL INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are required to
file annual, quarterly and special reports, proxy statements and other information with the SEC. You may read and copy any document
filed by us at the SEC&rsquo;s Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330
for further information on the public reference room. Our filings with the SEC are also available to the public at the SEC&rsquo;s
Internet web site at <I>http://www.sec.gov</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have filed a registration
statement, of which this prospectus is a part, covering the securities offered hereby. As allowed by SEC rules, this prospectus
does not include all of the information contained in the registration statement and the included exhibits, financial statements
and schedules. You are referred to the registration statement, the included exhibits, financial statements and schedules for further
information. This prospectus is qualified in its entirety by such other information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_013"></A>INCORPORATION OF CERTAIN INFORMATION
BY REFERENCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The SEC allows us to
&ldquo;incorporate by reference&rdquo; information from other documents that we file with it, which means that we can disclose
important information to you by referring you to those documents. The information incorporated by reference is considered to be
part of this prospectus. Information in this prospectus supersedes information incorporated by reference that we filed with the
SEC prior to the date of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We incorporate by reference
into this prospectus and the registration statement of which this prospectus is a part the information or documents listed below
that we have filed with the SEC (Commission File No. 001-35610):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 3%; text-align: justify"><FONT STYLE="font-family: Symbol">&middot; </FONT></TD>
    <TD STYLE="width: 90%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">our Annual Report on Form 10-K for the
        year ended December 31, 2014, filed with the SEC on March 30, 2015;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Symbol">&middot; </FONT></TD>
    <TD STYLE="text-align: justify">portions of our definitive Proxy Statement on Schedule 14A, filed with the SEC on April 15, 2015;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD>
    <TD STYLE="width: 3%; text-align: justify"><FONT STYLE="font-family: Symbol">&middot; </FONT></TD>
    <TD STYLE="width: 90%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">our current reports on Form 8-K filed with
        the SEC on April 7, 2015, as amended, May 14, 2015, May 18, 2015, May 28, 2015, June 4, 2015, June 10, 2015, September 4, 2015
        and October 10, 2015; and</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Symbol">&middot; </FONT></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">our Quarterly Reports on Form 10-Q for
        the quarter ended March 31, 2015, filed with the SEC on May 13, 2015, for the quarter ended June 30, 2015, filed with the SEC on
        August 6, 2015, and for the quarter ended September 30, 2015, filed with the SEC on November 12, 2015.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will furnish without
charge to you, on written or oral request, a copy of any or all of the documents incorporated by reference, including exhibits
to these documents. You should direct any requests for documents to Kyle Guse, Chief Financial Officer, Atossa Genetics Inc., 2300
Eastlake Ave. East, Suite 200, Seattle, Washington, 98102, telephone: (800) 351-3902. Copies of the above reports may also be accessed
from our web site at <I>http://www.atossagenetics.com</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any statement contained
in a document incorporated or deemed to be incorporated by reference in this prospectus will be deemed modified, superseded or
replaced for purposes of this prospectus to the extent that a statement contained in this prospectus modifies, supersedes or replaces
such statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Up to 6,086,207 shares of Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ATOSSA GENETICS INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_014"></A>PART II</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 13. Other Expenses of Issuance
and Distribution.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table sets forth the costs
and expenses, payable by the Company in connection with the registration and sale of the Common Stock being registered. All amounts
are estimates except the SEC registration fee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>Amount to be paid</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>($)</B></FONT></TD>
    <TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">SEC registration fee</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; padding-right: 0; padding-left: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">288</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="width: 87%"><FONT STYLE="font-size: 10pt">Printing expense</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; padding-right: 0; padding-left: 0; text-indent: 0; text-align: right">5,000</TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Legal fees and expenses</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; padding-right: 0; padding-left: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">50,000</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Accounting fees and expenses</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; padding-right: 0; padding-left: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">5,000</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Transfer Agent Fees</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; padding-right: 0; padding-left: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">2,000</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Miscellaneous Fees</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; padding-right: 0; padding-left: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">2,712</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Total</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; padding-right: 0; padding-left: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">65,000</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 14. Indemnification of Directors and Officers.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 145 of the
Delaware General Corporation Law, or the DGCL, authorizes a corporation to indemnify its directors and officers against liabilities
arising out of actions, suits and proceedings to which they are made or threatened to be made a party by reason of the fact that
they have served or are currently serving as a director or officer to a corporation. The indemnity may cover expenses (including
attorneys&rsquo; fees) judgments, fines and amounts paid in settlement actually and reasonably incurred by the director or officer
in connection with any such action, suit or proceeding. Section 145 permits corporations to pay expenses (including attorneys&rsquo;
fees) incurred by directors and officers in advance of the final disposition of such action, suit or proceeding. In addition, Section
145 provides that a corporation has the power to purchase and maintain insurance on behalf of its directors and officers against
any liability asserted against them and incurred by them in their capacity as a director or officer, or arising out of their status
as such, whether or not the corporation would have the power to indemnify the director or officer against such liability under
Section 145.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have adopted provisions
in our certificate of incorporation and bylaws that limit or eliminate the personal liability of our directors to the fullest extent
permitted by the DGCL, as it now exists or may in the future be amended. Consequently, a director will not be personally liable
to us or our stockholders for monetary damages or breach of fiduciary duty as a director, except for liability for:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 3%; text-align: justify"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 90%; text-align: justify">any breach of the director&rsquo;s duty of loyalty to us or our stockholders;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 3%; text-align: justify"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 90%; text-align: justify">any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 3%; text-align: justify"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 90%; text-align: justify">any unlawful payments related to dividends or unlawful stock purchases, redemptions or other distributions; or</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 3%; text-align: justify"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 90%; text-align: justify">any transaction from which the director derived an improper personal benefit.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 3%; text-align: justify"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 90%; text-align: justify">These limitations of liability do not alter director liability under the federal securities laws and do not affect the availability of equitable remedies such as an injunction or rescission.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, our bylaws
provide that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 3%; text-align: justify"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 90%; text-align: justify">we will indemnify our directors, officers and, in the discretion of our Board of Directors, certain employees to the fullest extent permitted by the DGCL, as it now exists or may in the future be amended; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 3%; text-align: justify"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 90%; text-align: justify">we will advance reasonable expenses, including attorneys&rsquo; fees, to our directors and, in the discretion of our Board of Directors, to our officers and certain employees, in connection with legal proceedings relating to their service for or on behalf of us, subject to limited exceptions.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 29; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have entered into
indemnification agreements with each of our directors and certain of our executive officers. These agreements provide that we will
indemnify each of these directors and executive officers to the fullest extent permitted by Delaware law. We will advance expenses,
including attorneys&rsquo; fees, judgments, fines and settlement amounts, to each indemnified director, executive officer or affiliate
in connection with any proceeding in which indemnification is available and we will indemnify our directors and officers for any
action or proceeding arising out of that person&rsquo;s services as an officer or director brought on behalf of the Company or
in furtherance of our rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We maintain general
liability insurance that covers certain liabilities of our directors and officers arising out of claims based on acts or omissions
in their capacities as directors or officers, including liabilities under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 15. Recent Sales of Unregistered
Securities.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has sold
the following securities within the past three years which were not registered under the Securities Act of 1933:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 20, 2012,
the Company issued an option to purchase 200,000 shares of its Common Stock to Christopher Destro as an inducement grant for the
employment of Mr. Destro as the Company&rsquo;s Vice President of Sales and Marketing. The option is exercisable at $4.11 per share
which was the fair market value on the date of grant. This transaction was exempt from registration under Section 4(a)(2) of the
Securities Act, as a transaction by an issuer not involving any public offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 4, 2013,
the Company issued options to purchase 500,000 shares of its Common Stock, exercisable at $4.11 per share which was the fair market
value on the date of grant, to Kyle Guse as an inducement grant for the employment of Mr. Guse as the Company&rsquo;s Chief Financial
Officer, General Counsel and Secretary. This transaction was exempt from registration under Section 4(a)(2) of the Securities Act,
as a transaction by an issuer not involving any public offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 13, 2013,
the Company issued a warrant to purchase 60,000 shares of Common Stock to a consultant as compensation for services to the Company.
The warrant has an exercise price of $4.25 per share which was the fair market value of the Company&rsquo;s Common Stock on the
date of grant. The warrant has a net-exercise feature and it vests monthly over one year so long as the consultant continues to
provide services to the Company. This transaction was exempt from registration under Section 4(a)(2) of the Securities Act, as
a transaction by an issuer not involving any public offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 24, 2013,
the Company issued 32,186 shares of Common Stock to consultants as compensation for the performance of services to the Company.
The aggregate value of shares issued was $143,550, or $4.46 per share, the fair market value of our Common Stock on the date of
issuance. This transaction was exempt from registration under Section 4(a)(2) of the Securities Act, as a transaction by an issuer
not involving any public offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 25, 2013
the Company issued 1,081,782 shares of Common Stock and on February 28, 2013 the Company issued 139,971 shares of Common Stock,
each upon exercise of outstanding warrants. These warrants were exercised on a &ldquo;net&rdquo; basis without additional consideration
received by the Company. These warrants were originally issued in 2011 in connection with the Company&rsquo;s private placement
to accredited investors pursuant to Rule 506 of Regulation D under the Act. This transaction was exempt from registration under
Section 4(a)(2) of the Securities Act, as a transaction by an issuer not involving any public offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 27, 2013 we
entered into a stock purchase agreement with Aspire Capital, and pursuant to that agreement we have sold common stock to Aspire
Capital with aggregate gross proceeds to us of approximately $11.3 million. This transaction was exempt from registration under
Section 4(a)(2) of the Securities Act, as a transaction by an issuer not involving any public offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From March through
November 2013, as placement agent fees in connection with the March 31, 2013 stock purchase agreement with Aspire Capital, we issued
warrants to Dawson James Securities, or its designee, to purchase a total of 67,000 shares of common stock at exercise prices ranging
from $2.12 to $12.43 per share. These transactions were exempt from registration under Section 4(a)(2) of the Securities Act, as
transactions by an issuer not involving any public offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 3, 2013, the
Company issued options to purchase 250,000 shares of its Common Stock, exercisable at $4.58 per share which was the fair market
value on the date of grant, to Peter Carbonaro as an inducement grant for the employment of Mr. Carbonaro as the Company&rsquo;s
Sr. Vice President of Operations. This transaction was exempt from registration under Section 4(a)(2) of the Securities Act, as
a transaction by an issuer not involving any public offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 8, 2013
the Company entered into a stock purchase agreement with Aspire Capital Fund, LLC, which provides that, upon the terms and subject
to the conditions and limitations set forth therein, Aspire Capital was committed to purchase up to an aggregate of $25 million
of shares of our Common Stock over the 30-month term of the agreement. Under the agreement, on November 8, 2013, Aspire Capital
was issued 375,000 shares of Common Stock as a commitment fee. These transactions were exempt from registration under Section 4(a)(2)
of the Securities Act, as transactions by an issuer not involving any public offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 1, 2014, the
Company issued options to purchase 300,000 shares of its Common Stock, exercisable at $1.69 per share which was the fair market
value on the date of grant, to Ben Chen as an inducement grant for the employment of Mr. Chen as the Company&rsquo;s Sr. Vice President
of Global Regulatory Affairs and Quality Assurance. This transaction was exempt from registration under Section 4(a)(2) of the
Securities Act, as a transaction by an issuer not involving any public offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 2, 2014, the
Company issued options to purchase 200,000 shares of its Common Stock, exercisable at $1.41 per share which was the fair market
value on the date of grant, to John Sawyer as an inducement grant for the employment of Mr. Sawyer as the Company&rsquo;s Sr. Vice
President of Global Regulatory Affairs and Quality Assurance. This transaction was exempt from registration under Section 4(a)(2)
of the Securities Act, as a transaction by an issuer not involving any public offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On September 2, 2014,
the Company issued options to purchase 200,000 shares of its Common Stock, exercisable at $1.86 per share which was the fair market
value on the date of grant, to Scott Youmans as an inducement grant for the employment of Mr. Youmans as the Company&rsquo;s Sr.
Vice President of Operations. This transaction was exempt from registration under Section 4(a)(2) of the Securities Act, as a transaction
by an issuer not involving any public offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 15, 2014,
the Company issued options to purchase 200,000 shares of its Common Stock, exercisable at $0.96 per share which was the fair market
value on the date of grant, to Pieter Van der Poel as an inducement grant for the employment of Mr. Van der Poel as the Company&rsquo;s
Vice President of European Commercial Operations. This transaction was exempt from registration under Section 4(a)(2) of the Securities
Act, as a transaction by an issuer not involving any public offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 23, 2013
the Company issued 500,000 shares of Common Stock to Aspire Capital with gross proceeds to the Company of $1,000,000. These shares
were issued upon achievement of a regulatory milestone as required by the November 8, 2013 agreement with Aspire Capital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From March 4, 2015
to March 31, 2015 we sold 2,653,199 shares of Common Stock to Aspire Capital under the November 8, 2013 agreement with them, with
total gross proceeds to the Company of $4,292,349.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 4, 2015, the
Company issued options to purchase 200,000 shares of its Common Stock, exercisable at $1.44 per share which was the fair market
value on the date of grant, to Cindy Atha as an inducement grant for the employment of Ms. Atha as the Company&rsquo;s Vice President
of Sales and Marketing. This transaction was exempt from registration under Section 4(a)(2) of the Securities Act, as a transaction
by an issuer not involving any public offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 26, 2015 Company
entered into a stock purchase agreement with Aspire Capital Fund, LLC, which provides that, upon the terms and subject to the conditions
and limitations set forth therein, Aspire Capital was committed to purchase up to an aggregate of $25 million of shares of our
Common Stock over the 30-month term of the agreement. Under the agreement, on May 26, 2015, Aspire Capital was issued 375,000 shares
of Common Stock as a commitment fee. These transactions were exempt from registration under Section 4(a)(2) of the Securities Act,
as transactions by an issuer not involving any public offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 26, 2015, the
Company issued options to purchase 100,000 shares of its Common Stock, exercisable at $1.49 per share which was the fair market
value on the date of grant, to Dr. Gerald Engley as an inducement grant for the employment of Mr. Engley as the Company&rsquo;s
Sr. Director of Medical Affairs. This transaction was exempt from registration under Section 4(a)(2) of the Securities Act, as
a transaction by an issuer not involving any public offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 12, 2015,
the Company issued options to purchase 200,000 shares of its Common Stock, exercisable at $0.79 per share which was the fair market
value on the date of grant, to Janet Rea as an inducement grant for the employment of Ms. Rea as the Company&rsquo;s Vice President
of Regulatory Affairs and Quality. This transaction was exempt from registration under Section 4(a)(2) of the Securities Act, as
a transaction by an issuer not involving any public offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 11, 2015
Company entered into a stock purchase agreement with Aspire Capital Fund, LLC, which provides that, upon the terms and subject
to the conditions and limitations set forth therein, Aspire Capital was committed to purchase up to an aggregate of $25 million
of shares of our Common Stock over the 30-month term of the agreement. Under the agreement. This transaction was exempt from registration
under Section 4(a)(2) of the Securities Act, as a transaction by an issuer not involving any public offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 16. Exhibits and Financial Statement
Schedules.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">See Exhibit Index set
forth on page II-6 to this Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 17. Undertakings.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The undersigned registrant
hereby undertakes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(1) To file, during
any period in which offers or sales are being made, a post-effective amendment to this registration statement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(i) To include any
prospectus required by Section 10(a)(3) of the Securities Act of 1933;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(ii) To reflect in
the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective
amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the
registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar
value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated
maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate,
the changes in volume and price represent no more than a 20 percent change in the maximum aggregate offering price set forth in
the &ldquo;Calculation of Registration Fee&rdquo; table in the effective registration statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(iii) To include any
material information with respect to the plan of distribution not previously disclosed in the registration statement or any material
change to such information in the registration statement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(2) That, for the purpose
of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration
statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the
initial <I>bona fide</I> offering thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(3) To remove from
registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination
of the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(4) That, for the purpose
of determining liability under the Securities Act of 1933 to any purchaser: each prospectus filed pursuant to Rule 424(b) as part
of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses
filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first
used after effectiveness; <I>provided, however</I> , that no statement made in a registration statement or prospectus that is part
of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement
or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such
first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration
statement or made in any such document immediately prior to such date of first use.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Insofar as indemnification
for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers, and controlling persons of the
registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities
and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable.
In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred
or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding)
is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant
will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate
jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed
by the final adjudication of such issue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_015"></A>SIGNATURES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that
it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-1 and has duly caused this Registration
Statement on Form S-1 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Seattle, State of
Washington, on November 27, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">Atossa Genetics Inc.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 95%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Steven C. Quay</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><B>Steven C. Quay, M.D., Ph.D.</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><B>Chairman, Chief Executive Officer and President</B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>POWER OF ATTORNEY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">KNOW ALL PERSONS BY
THESE PRESENTS, that each person whose signature appears below constitutes and appoints Steven C. Quay, M.D., Ph.D. and Kyle Guse
as attorneys-in-fact, with power of substitution, in any and all capacities, to sign any and all amendments and post-effective
amendments to this registration statement, and to file the same, with all exhibits thereto and other documents in connection therewith,
with the Securities and Exchange Commission, hereby ratifying and confirming all that said attorneys-in-fact, or their substitute
or substitutes, may do or cause to be done by virtue thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements of the Securities Act of 1933,
as amended, this Registration Statement on Form S-1 has been signed by the following persons in the capacities and on the dates
indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 28%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Signature </B></FONT></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 50%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Office(s) </B></FONT></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 20%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Date </B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Steven C. Quay</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Chairman, Chief Executive</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">November 27, 2015</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt"><B>Steven C. Quay, M.D., Ph.D. </B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Officer and President</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Principal Executive Officer)</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Kyle Guse</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">Chief Financial Officer, General Counsel and Secretary</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">November 27, 2015</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt"><B>Kyle Guse </B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Principal Financial and Accounting Officer)</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Shu-Chih Chen</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Director</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">November 27, 2015</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt"><B>Shu-Chih Chen, Ph.D. </B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Stephen J. Galli</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Director</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">November 27, 2015</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt"><B>Stephen J. Galli, M.D. </B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ H. Lawrence Remmel</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Director</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">November 27, 2015</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt"><B>H. Lawrence Remmel </B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Gregory L. Weaver</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Director</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">November 27, 2015</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt"><B>Gregory L. Weaver </B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Richard Steinhart</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Director</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">November 27, 2015</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt"><B>Richard I. Steinhart </B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_016"></A>EXHIBIT INDEX</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Incorporated by Reference Herein </B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; width: 12%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Exhibit No. </B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 50%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Description </B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 25%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Form </B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Date </B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.1&dagger;&dagger;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Agreement and Plan of Reorganization, dated September 30, 2012, by and among the Company, Acueity Healthcare, Inc., and Ted Lachowicz, as Stockholder Representative</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Registration Statement on Form S-1, as Exhibit 2.1</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">October 4, 2012</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Certificate of Incorporation of Atossa Genetics Inc.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Registration Statement on Form S-1, as Exhibit 3.2</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">June 11, 2012</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.2</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Bylaws of Atossa Genetics Inc.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Registration Statement on Form S-1, as Exhibit 3.4</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">June 11, 2012</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.3</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Amendment to Bylaws of Atossa Genetics Inc.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Current Report on Form 8-K, as Exhibit 3.1</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">December 20, 2012</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">3.4</P></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Certificate of Designations, Preferences and Rights of Series A Junior Participating Preferred Stock</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Current Report on Form 8-K, as Exhibit 3.1</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">May 22, 2014</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Specimen Common Stock Certificate</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Registration Statement on Form S-1, as Exhibit 4.1</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">May 21, 2012</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.2</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Form of Warrant from 2011 private placement</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Registration Statement on Form S-1, as Exhibit 4.2</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">October 4, 2012</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.3</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Form of Placement Agent Warrant from 2011 private placement</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Registration Statement on Form S-1, as Exhibit 4.3</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">October 4, 2012</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.4</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Form of Warrant dated September 30, 2012</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Registration Statement on Form S-1, as Exhibit 4.4</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">October 4, 2012</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.5</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Form of Warrant Agreement from January 2014 Public Offering</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Current Report on Form 8-K, as Exhibit 4.1</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">January 20, 2014</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.6</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Form of Warrant issued to Dawson James Securities Inc. in January
        2014</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Current Report on Form 8-K, as Exhibit 4.2</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">January 20, 2014</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">4.7&nbsp;</P></TD>
    <TD>&nbsp;</TD>
    <TD>
        <P>Rights Agreement between the Company and VStock Transfer, LLC, dated May 19, 2014</P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Current Report on Form 8-K, as Exhibit 3.1</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">May 22, 2014&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.8</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Form of Pre-Funded Warrant from June 5, 2015 offering</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Current Report on Form 8-K, as Exhibit 4.1</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">June 10, 2015</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.9</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Registration Rights Agreement between the Company and Aspire Capital Fund, LLC, dated November 11, 2015</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Quarterly Report on Form 10-Q, as Exhibit 10.2</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">November 12, 2015</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">5.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Opinion of Gibson, Dunn &amp; Crutcher, LLP&nbsp;</P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Filed herewith</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.1#</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Restated and Amended Employment Agreement with Steven Quay</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Registration Statement on Form S-1, as Exhibit 10.3</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">February 14, 2012</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.2#</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Restated and Amended Employment Agreement with Shu-Chih Chen</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Registration Statement on Form S-1, as Exhibit 10.4</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">February 14, 2012</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 12%">10.3</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 50%">Form of Indemnification Agreement</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 25%; text-align: center">Registration Statement on Form S-1, as Exhibit 10.5</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: center">May 21, 2012</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>10.4#</TD>
    <TD>&nbsp;</TD>
    <TD>Atossa Genetics Inc. 2010 Stock Option and Incentive Plan, as amended</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Registration Statement on Form S-1, as Exhibit 10.6</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">June 11, 2012</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>10.5#</TD>
    <TD>&nbsp;</TD>
    <TD>Form of Incentive Stock Option Agreement</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Registration Statement on Form S-1, as Exhibit 10.7</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">June 11, 2012</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 12%">10.6#</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 50%">Form of Non-Qualified Stock Option Agreement for Employees</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 25%; text-align: center">Registration Statement on Form S-1, as Exhibit 10.8</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: center">June 11, 2012</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>10.7#</TD>
    <TD>&nbsp;</TD>
    <TD>Form of Non-Qualified Stock Option Agreement for Non-Employee Directors</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Registration Statement on Form S-1, as Exhibit 10.9</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">June 11, 2012</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>10.8</TD>
    <TD>&nbsp;</TD>
    <TD>Form of Subscription Agreement</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Registration Statement on Form S-1, as Exhibit 10.10</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">February 14, 2012</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>10.9</TD>
    <TD>&nbsp;</TD>
    <TD>Sublease Agreement with CompleGen, Inc. dated September 29, 2010</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Registration Statement on Form S-1, as Exhibit 10.11</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">February 14, 2012</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>10.10</TD>
    <TD>&nbsp;</TD>
    <TD>Patent Assignment Agreement by and between the Company and Ensisheim Partners, LLC</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Registration Statement on Form S-1, as Exhibit 10.12</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">April 6, 2012</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>10.11#</TD>
    <TD>&nbsp;</TD>
    <TD>Form of Restricted Stock Award Agreement</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Registration Statement on Form S-1, as Exhibit 10.13</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">June 11, 2012</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>10.12</TD>
    <TD>&nbsp;</TD>
    <TD>Business Consultant Agreement with Edward Sauter</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Registration Statement on Form S-1, as Exhibit 10.16</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">February 14, 2012</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>10.13</TD>
    <TD>&nbsp;</TD>
    <TD>Prototype Development Proposal and Terms and Conditions, between the Company and HLB, LLC</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Registration Statement on Form S-1, as Exhibit 10.17</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">February 14, 2012</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>10.14</TD>
    <TD>&nbsp;</TD>
    <TD>Office Lease with Sander Properties, LLC, dated March 4, 2011</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Registration Statement on Form S-1, as Exhibit 10.20</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">April 6, 2012</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>10.15</TD>
    <TD>&nbsp;</TD>
    <TD>Office Lease with Sander Properties, LLC, dated July 8, 2011</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Registration Statement on Form S-1, as Exhibit 10.21</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">April 6, 2012</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>10.16</TD>
    <TD>&nbsp;</TD>
    <TD>Office Lease with Sander Properties, LLC, dated September 20, 2011</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Registration Statement on Form S-1, as Exhibit 10.22</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">April 6, 2012</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>10.17</TD>
    <TD>&nbsp;</TD>
    <TD>Sublease with Fred Hutchinson Cancer Research Center, dated December 9, 2011</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Registration Statement on Form S-1, as Exhibit 10.23</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">April 6, 2012</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>10.18</TD>
    <TD>&nbsp;</TD>
    <TD>Promissory Note &mdash; Line of Credit, effective November 3, 2010, by and between the Company and Steven C. Quay</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Registration Statement on Form S-1, as Exhibit 10.24</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">May 21, 2012</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>10.19&dagger;</TD>
    <TD>&nbsp;</TD>
    <TD>Term Sheet for License Agreement between the Company and Inven2 AS</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Registration Statement on Form S-1, as Exhibit 10.25</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">June 25, 2012</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>10.20&dagger;</TD>
    <TD>&nbsp;</TD>
    <TD>Agreement between the Company and Accellent Inc., dated August 8, 2011</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Registration Statement on Form S-1, as Exhibit 10.26</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">June 25, 2012</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>10.21&dagger;</TD>
    <TD>&nbsp;</TD>
    <TD>Supply Agreement between the Company and Biomarker LLC, dated June 24, 2011</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Registration Statement on Form S-1, as Exhibit 10.27</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">June 18, 2012</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>10.22&dagger;</TD>
    <TD>&nbsp;</TD>
    <TD>Purchase Agreement between the Company and Hologic Inc., dated May 11, 2011</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Registration Statement on Form S-1, as Exhibit 10.28</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">June 25, 2012</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 12%">10.23</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 50%">Agreement between the Company and Biomarker LLC, dated June 22, 2012</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 25%; text-align: center">Registration Statement on Form S-1, as Exhibit 10.29</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: center">June 25, 2012</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>10.24</TD>
    <TD>&nbsp;</TD>
    <TD>Form of Investor Lock-Up Agreement</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Registration Statement on Form S-1, as Exhibit 10.30</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">August 30, 2012</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>10.25&dagger;</TD>
    <TD>&nbsp;</TD>
    <TD>Supply and Distribution Agreement, dated as of September 21, 2012, between the Company and Diagnostics Test Group LLC</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Registration Statement on Form S-1, as Exhibit 10.31</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">October 4, 2012</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 12%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.26</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 50%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Employment Agreement between the Company and Kyle Guse dated January 4, 2013#</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 25%; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Registration Statement on Form S-1, as Exhibit 10.31</FONT></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">January 28, 2013</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.27</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Purchase Agreement, dated as of March 27, 2013, by and between the Company and Aspire Capital Fund, LLC</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Annual Report on Form 10-K, as Exhibit 10.30</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">March 28, 2013</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.28</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Purchase Agreement, dated as of November 8, 2013, by and between the Company and Aspire Capital Fund, LLC</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Quarterly Report on Form 10-Q, as Exhibit 10.2</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">November 12, 2013</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.29</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">OwnerChip Program Agreement dated September 1, 2013, by and between The National Reference Laboratory for Breast Health, Inc. and Affymetrix, Inc.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Quarterly Report on Form 10-Q, as Exhibit 10.1</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">November 12, 2013</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.30</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">License and Services Agreement dated June 10, 2013, between Atossa Genetics and A5 Genetics KFT</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Annual Report on Form 10-K, as Exhibit 10.32</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">March 27, 2014</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.31</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Office Space Lease dated July 18, 2013 between Alexandria (ARE) and the Company</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Annual Report on Form 10-K, as Exhibit 10.33</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">March 27, 2014</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.32</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Common Stock Purchase Agreement, dated as of November 8, 2013, by and between the Company and Aspire Capital Fund, LLC</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Quarterly Report on Form 10-Q, as Exhibit 10.2</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">November 12, 2013</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.33</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Lab and Office Space Lease Agreement dated March 24, 2014 between Alexandria (ARE) and the Company</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Annual Report on Form 10-K, as Exhibit 10.35</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">March 27, 2014</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.34</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Offer Letter Agreement dated March 20, 2014 between the Company and Ben Chen#</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Post-Effective Amendment No. 1 to Registration Statement on Form S-1, as Exhibit 10.34</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">April 28, 2014</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.35#</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Offer Letter Agreement with Peter Carbonaro dated May 23, 2013.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Quarterly Report on Form 10-Q, as Exhibit 10.1</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">May 14, 2014</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.36#</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Offer Letter Agreement with Chris Destro dated November 12, 2012.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Quarterly Report on Form 10-Q, as Exhibit 10.2</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">May 14, 2014</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.37</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Office Space Assignment and Assumption of Lease and Consent to Assignment dated August 8, 2014 between Legacy Group, Inc. and the Company.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Quarterly Report on Form 10-Q, as Exhibit 10.1</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">August 12, 2014</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.38</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">TME Master Service Agreement dated September 1, 2014 between Targeted Medical Education (TME) and NRLBH</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Quarterly Report on Form 10-Q, as Exhibit 10.2</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">November 12, 2014</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.39#</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Offer Letter Agreement with John Sawyer dated May 23, 2014.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Annual Report on Form 10-K, as Exhibit 10.30</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">March 30, 2015</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.40</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Intellectual Property License Agreement with Besins Healthcare Luxembourg SARL</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Current Report on Form 8-K, as Exhibit 10.1</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">May 18, 2015</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 12%">10.40</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 50%">Placement Agent Agreement dated June 5, 2015 among the Company, Roth Capital Partners, LLC and Dawson James Securities, Inc.</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 25%; text-align: center">Current Report on Form 8-K, as Exhibit 10.1&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: center">June 10, 2015</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>10.41</TD>
    <TD>&nbsp;</TD>
    <TD>Form of Subscription Agreement from June 5, 2015 offering.</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Current Report on Form 8-K, as Exhibit 10.2</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">June 10, 2015</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>10.42</TD>
    <TD>&nbsp;</TD>
    <TD>Common Stock Purchase Agreement, between the Company and Aspire Capital Fund, LLC, dated as of November 11, 2015</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Quarterly Report on Form 10-Q, as Exhibit 10.1</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">November 12, 2015</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>21.1</TD>
    <TD>&nbsp;</TD>
    <TD>List of Subsidiaries</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Registration Statement on Form S-1, as Exhibit 21.1</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">October 4, 2012</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>23.1</TD>
    <TD>&nbsp;</TD>
    <TD>Consent of KCCW Accountancy Corp.</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Filed herewith</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">23.2</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">23.2</P></TD>
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Consent of BDO USA, LLP</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Consent of Gibson, Dunn &amp; Crutcher, LLP</P></TD>
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Filed herewith</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Filed as part of Exhibit 5.1 to this Registration
        Statement on Form S-1</P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>24.1</TD>
    <TD>&nbsp;</TD>
    <TD>Powers of Attorney</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Included on the signature page in Part II of this Registration Statement on Form S-1</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 3%">#</TD>
    <TD STYLE="width: 96%; text-align: justify">Indicates management contract or compensatory plan, contract or agreement.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 3%">&dagger;</TD>
    <TD STYLE="width: 96%">Confidential treatment has been granted for portions of this exhibit. These portions have been omitted from the Registration Statement and submitted separately to the Securities and Exchange Commission.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 3%">&dagger;&dagger;</TD>
    <TD STYLE="width: 96%">Schedules and exhibits omitted pursuant to Item 601 of Regulation S-K.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 37; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>v425502_ex5-1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 5.1</B></P>

<P STYLE="margin: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="margin: 0; text-align: right"><B></B></P>



<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="image_004.jpg" ALT=""><B>&nbsp;</B></P>

<P STYLE="margin: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="margin: 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Client: 05637 - 00003</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">November 25, 2015</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Atossa Genetics Inc.<BR>
2300 East Lake Ave., East, Suite 200</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Seattle, Washington 98102</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.35in">Re:</TD><TD>Atossa Genetics Inc.<BR>
<I>Registration Statement on Form&nbsp;S-1</I></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35in; text-indent: -0.35in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35in; text-indent: -0.35in">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have examined the Registration Statement
on Form S-1 (the &ldquo;<U>Registration Statement</U>&rdquo;), of Atossa Genetics Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;),
filed with the Securities and Exchange Commission (the &ldquo;<U>Commission</U>&rdquo;) pursuant to the Securities Act of 1933,
as amended (the &ldquo;<U>Securities Act</U>&rdquo;), in connection with the offering by the Company of up to 6,086,207 shares
of the Company&rsquo;s common stock, par value $0.001 per share, (the &ldquo;<U>Shares</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In arriving at the opinion expressed below,
we have examined originals, or copies certified or otherwise identified to our satisfaction as being true and complete copies of
the originals, of specimen common stock certificates and such other documents, corporate records, certificates of officers of the
Company and of public officials and other instruments as we have deemed necessary or advisable to enable us to render the opinions
set forth below. In our examination, we have assumed without independent investigation the genuineness of all signatures, the legal
capacity and competency of all natural persons, the authenticity of all documents submitted to us as originals and the conformity
to original documents of all documents submitted to us as copies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Based upon the foregoing, and subject to
the assumptions, exceptions, qualifications and limitations set forth herein, we are of the opinion that the Shares, when issued
against payment therefor as set forth in the Registration Statement, will be validly issued, fully paid and non-assessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We consent to the filing of this
opinion as an exhibit to the Registration Statement, and we further consent to the use of our name under the caption
&ldquo;<U>Legal Matters</U>&rdquo; in the Registration Statement and the prospectus that forms a part thereof. In giving
these consents, we do not thereby admit that we are within the category of persons whose consent is required under Section 7
of the Securities Act or the Rules and Regulations of the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Sincerely yours,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Gibson, Dunn &amp; Crutcher LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt; text-transform: uppercase"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_002.jpg" ALT="" STYLE="height: 26px; width: 424px"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt; text-transform: uppercase"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase">&nbsp;</P>



<P STYLE="margin: 0; text-align: left"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>v425502_ex23-1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 23.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><IMG SRC="image_005.jpg"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC
ACCOUNTING FIRM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We hereby consent to the use in this Registration Statement
on Form S-1 of Atossa Genetics Inc. of our report dated March 26, 2014 relating to the consolidated financial statements as of
and for the year ended December 31, 2013 appearing in the Prospectus, which is part of this Registration Statement. We also consent
to the reference to us under the heading &ldquo;Experts&rdquo; in such Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ KCCW Accountancy Corp.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">KCCW Accountancy Corp.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Diamond Bar, California</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">November 25, 2015</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>4
<FILENAME>v425502_ex23-2.htm
<DESCRIPTION>EXHIBIT 23.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 23.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Consent of Independent Registered Public
Accounting Firm</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Atossa Genetics Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Seattle, Washington</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We hereby consent to the incorporation
by reference in the Prospectus constituting a part of this Registration Statement on Form S-1 of our report dated March 30, 2015,
relating to the consolidated financial statements of Atossa Genetics Inc., which is incorporated by reference in that Prospectus.
Our report contains an explanatory paragraph regarding the Company&rsquo;s ability to continue as a going concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We also consent to the reference to us
under the caption &ldquo;Experts&rdquo; in the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ BDO USA, LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">BDO USA, LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Seattle, Washington</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">November 25, 2015</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  : :@# 2(  A$! Q$!_\0
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MF>HJ_!H.F6T2QQ6V%7R\9=B?D<R+R3SAF)_&FQ^'=,B<&.!T41^6465PK#!
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M99<=3D=.HB&HG5+KSS:G33&@@"!O-W\[]^>,=,8]ZNT4 >;00:U%>1K)!?O
M)?L+ !C^[M294D _Z:89<]\@59M->U]C%+,\S0"X"A%@_>2JRQG )C"G!+@C
MY?9CMKT"B@#A]+;6;:"UMY5FGB,D+XE@SY6;A@P!QGA<')R1UJ&;6]?L[:V:
MYDNF:Y$9(CME$BL?-RJ J1QM0G()QD]Z[ZJU]:V]W;%+F"*9000LB!@#Z\T
M<5::CJ*32S/J\[PS_9FDN88!(B+Y+9>,;,8,@"GCC/0'FM&PU/6Q/!=:EYD4
M&\K/!]G^6-!;"0MG&[._(ZX[=:ZN.-(HUCC1411A548 'H!2D!@00"#P0>]
M'/>()+>YBTB:;SWL))]\GE+)DJ8GVY"?-UV_CBJ3RW+:-I4.I"],<<@-\ K[
M_+*OY>XKR>0F['?KQ77]** *&D31M8Q0H+L&.-3B[4^9M.<;B>IP/J._-%7Z
$* /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_004.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !* L$# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HKC[[3;EM8U+R([EC=I*LLAM4^2,
MP!5\N3.2=P'RDXY.0,9JC-IMRUC'LM;CRK>63[(@T^/]X3&N#)'@!?GW ' X
MZD=2 =Z64$ L 6Z GK2"2,MM#J3R, ^G6N5\4V>I7 TB^MK,SWFGF2Z$<;8!
MD$?W 3_>RR9_VJR[+2-9TNSG@A\^)GDN99)XX@[&1_*8L!G)RWF="#^(% '?
MLP52S$!0,DGH*6N#:3Q&R-B&^=I+*6-8G&51@C[7R1A]Q"_*P5AD=1FK%R/$
M3W5S'"U^A9RKE0OEK'YL?EF(D=?+WY_'/:@#LV944LQ"J!DDG  I$=)$5T96
M5AD,IR"*YVYL[FY\)75I?1WEPRSN%"%3*T:S$H?F^5OE"G!^\."#FN?6RUB.
M!9[6VNK:9+:]BM6MX?*5G;RV1WB)(5B0_!X)4' SB@#T2BN&O8_%,%[?16EQ
M<N(T*V^Z/<)(]B_-NX42;M_;)/'3!JUHEKJ U^UN[U[Z139RQ*[H408ERH93
MDYVG@GDXH Z^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#'A\0V\^K75BD$P2
MU8I-<$J$1@N[YAG<!CHQ&#Z]*F/B'1Q%'(VI6H24E4)D R1C/Y;A^8JAJ/AF
M;4-3^UG4C$4WF&2.!1-%N0KM$G=,L6VD=<<\56A\%I';W<;7Q+7,<\;%(\ >
M:L2D\L2<>4#R3G)H UM4UI=-N[2U6UEN)[D.R*CH@ 7;G)=A_>' IQU_2E+*
M^H6RLDGDNOF@[''53CH1W]*6]T>WO]4LKVX5)/LB2*L;QA@2Y7YN>A&S]:R=
M2\'B_L39I?M%"\EQ)(OEY#&63?G (!9<D G(Y/&<$ &O_;FE!KA?[0MLVV?.
M'F#Y,':0??/'UXIK:]IJ)YKWD"P%$=9?-7#!MV,<Y_@;\CZ'%"?PN)6CD2\9
M)(I)98R8P0'>X6?D9Y *XQW'H:2]\,27H>22]3[2Z1J9?(QL9#)\R;6!4_O3
MR#VYSDT :;ZWI<<D\;7]N'MUW2J9!E1Q_B/S'J*MV]Q#=6Z3V\J2PR#<KH<@
MCZU@KX9G2W^SC4RT<<PN(3) "PEWB0ESD;@6!X&/O=>!B_I6GW.G!H'N$EM]
MI?[FUC*SN\C>RG<,#MCK0! OBBQ:TN+LPW:V\41F20P'$Z9QF/U)., X)R.,
M&K4VL6T6G6UZHDE2Z*"!(URTA89  ^G//3!K-7PQ,UE!I\^JROI]NT8CA1/+
M;8C;E#.#DD;4&1C@=,G-68_#\<.@C2D=)(DD+0FX0OL&\LH^\"2N< YSP* '
MCQ%IY;3TW2^9?2-%&GEG*,N=V_\ NX*E?KQ2G7K81S-Y-R9([K[((1'\[R8#
M?+SC&TYR2. :SX/!=G;?8&@N[J)K5U=O+?:LF"YP5Z %I&/'K5G^P;CS)YA?
MH)FOOMD+>1PAV>658;OF!7/IUH EM_$5G=WD%M LK231B3G:NP99<$$@Y!1@
M0 <8J6ZURTL[[[+(LI(V"215RD1<X3<?<^F<=\507PN!]G5KE&1&225S;J)7
M=9&DR'!RH+,>.<#.,9-2R^'%:Y9HKITMI6A:>)\R,YC;<N'8Y&> <YX'&* '
M0^);2XCW16]XS,J211B+YID<D*Z\_=XZG&.^,BI[77;2[FLHXEF_TN-Y(V*8
M V$!E/H1G]*RSX0VM=26UW%;2W&R-C# 57RE8L4P'R,EN2"..@%:(TB47VF3
MK<0)'91/&88[?:K!@!Q\WR@8''- &M1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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1;HH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_005.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !+ I,# 2(  A$! Q$!_\0
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M#9^%O!^EGAH[!KIA_P!=6S_0UW?C7QSH/BG04T+2+UY[F^NH8BGDNGR[P>K
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M*GD]^]6KO7);HVMT=#\7'4[6=IXKB32=R LNTIY>\?)CL"#WSG-=QIVLI=W
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M(7=R ,C.WOMS6W15<\K6N!Q^E^#9M[3ZM=S&52BP+%<[S&B(Z*-_EH>/,8C
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>tpg04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tpg04.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ 9P$2 P$1  (1 0,1 ?_$ .8   $#! ,!
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MW@'Q'W)F-[1(;;4@]/JC[M0F63\P&ZC2BP^^2 ;%=-A\L9C?4# 5H5/8XD@
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MK3B35[^<;1-(#*G&-5C1(H =!*:@AI""NB<B;E%;SR07IK;ZC08Y>S'! _\
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MK6XY#SEN2)B%$%CM ;JBCN_%[/TZ,2WP6J<QV8AO304+OJ3>?UG<RJ_%GC^
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M(Y7Y'VMD3G CRP,]3$4J#$["G#L*&GR3XZV]EW)&2\H\)+*?75A:$%)G/.F
M)MXZ(G6S4JTHVA 6."JC40*)Q,%2E#PTK;43,,@!-,Z9!=KZ*=5=QY'V.SY6
MZB.ACYS,KW/%PUHF+)':HP1(2_[)%.'8AUJ)F24.F<0W)&,F<I#$,5,Y!V'2
M R8F*/;. @/7Q#6'G>8ZZ5]Z[9O&Q;YMK;R6OK::^5P R[ J:OW9>OXX_P"#
M_<U7A>Z2<%V:P&]S"?8KIPKI;&\"O90J>QQ*_LUX6_J\M[^0H:V.3[O@%^=_
MJC_4W<?XB3XE;SECR*<>\-#II+2QFCTL:DXWE:JOP;*&9D=JD 3(MA< 7>8
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M;@/ZMGI@9'GWO&=KBOD;BN[5RDG;4D+F-;C:9,W6 K21*U?BF$3/ @4"'<$
MQ/V-)19RYO-MW3\6^/XG<=/N6Z^0W KU+_5'O2QAY>GQIQDP99#L[TN/;'N!
M6]+ADUW9D2/5U7+&K<7Y$""#=0P42.-=&>:J,O+':G^KM^,G>0Y'KXK<6<3<
M/\2V_B##\*,9;L8V1,Z<K"!YFXI@I0!U/3;@"$%5\L'B8?   /9I0>"UW>=R
MN]VD$ER02#A04 _3BMMY2QY'90QO?..YHP)1U\6W-6V]-U.F9M+QZS(QE"@
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M'JJ%\Q(-DR 0K:3:E#[-0"B(%"@UU.VZ+!I P*^9OF8Z%6'56V9NEC&+3=&
MEL@J_$_YNM@Q[T<>X>0W"^9FL;\X;9N6/LV_ DXZTI^W8XQ0EKIB9Y4C60M^
M[XI,Z0JE8+""Q%QJ)1#Z=69)VM8)6FH.'9[*4]Z\P.9^1>IVPVDW*4UK+=F(
M:F.+HVD"I#7 ZSA_FUP33_6<P,V2N''O*2UR(.+9R'%M[?N)XU1+V?-ND$UH
M9\NJF(DV/4"@F!A -A@*6HUKJM+%CKR/'].\+ZD^1OJ3-:Z^GO,#=%Y:%[0"
M<?,<O*TC \=6-4%W'=M1UV7Q:%JRDNSAHF7G&,7,23IRB@V810N %TLNJX$4
MRJ;1$"&$ Z  ZA].IS7WQSSOC>5-ANK^P;6X],EK0<R!AB00C[F]&CCY?#5K
M-XYY+O&T:];H&[!7D'.M1."9?- Q.5VW,7:I7H) I]/CJ5]O0D# #VKS&9\Y
M?-FUB7E_>=K<YT<KR'"1@J'.)%0(G4IVZCX)B_/CA9B#BO:]DGQWEA.^+D<2
M9V%QLG<NQ5?J-5$1.@X&.9&6*@0BA1 I1&OTZ1\+6M'[R^COEFZV[IU+YAEB
MW6$[?M['>5V$@/:#1K37V (8*O;*A5.H@F)1,(]!.8^T1Z"([=HFI^QJ$6NJ
M02UR[E]P\Y7-KN&T3S6&,+('-)QQ(!QQI2JGM\3"B'&W"Y?_ ,=V]U_]P0]F
MLE(<NX!?G&ZHFG4W<>S\Q)\2M]J)*&4 I=IB;2D$#%W .\0(;>6H;B 0>H:@
M?@:]JYP(R[<7S TTNR6/R5K05QL58Z=AX>58@4Z8L)>/:RC=, 5'MB8KI,QA
M3'97: A33#CX+-7&J9@Q(?\ ']2]2,B(ZUD!;P\='M&!RB9-G',V<<5$$REV
M(H)-DD4SH@41&INI0#Q'2<%!5SVAG%H5\N=)^4@D%,Q$ZJ4,*2J"Q#DV_$.T
M_P .[I4H@(#I%$[4T5HO)D(B(=+(BI&L73IJ4$T0<(%=*D!4HG.DD9?<4$]I
M:@ _#4 TX4'>IK65P>2,!IQ75I$0K%5(T>QCV92IJD[[9NU04 JPE!R0QT/$
M#*;=U"A^'243)6&5VLGS+V3)'^T%-0=IC)]XH4.4ADR;2)I ;H!1\3#0:Z1+
M$_TS6FI>2LS8R"Y49!DV=B1<_9!VBDZV'% W=3(0YEP(!D:]3 3IX==.J%&^
M=P^RVA\5RYBF(QAT';9LZCBI) Y9.6I'34J#2IR DT5WE 4Q #  U *= KI0
M!2JKP32-G:ZA(\:<%?M%TC* 0FTF[LF1(4R8=Y),G10FPYP!(2] *(%'3<"I
MYI'.-=."]!8X*HG Z6X@E.50@UJ8HA0P4"@C4/9[=+3"JBCG?JT!N9IFL(;V
M];;P2 C!P?8'94Y(Z/*9!<Q"J=E0"%[Y7:2A-QRGK4!ZCI/@LBR=\6 %2%DI
M(=%LFFDT*BBV2 !!GV@\F ID*"()H 8"($3$!-0H &X:Z*A4Y)B]]2W&O:KS
MS9=X)"006&@F0[B0K=D>@N"IE.)S(U]M*_1HS1*YQ%*+R%[:B%G*CE6,C5U5
MC%,HJXCF:S@!32[:8E<&2[QQ#QJ<3Z44XJ-EW)"<&X^*OO.-FFQ!)-'MH D;
MMHF(F=),YNWN[0COW@H(!MH'33:=JD+G9T7L"J(?B?NAI0 H'3N;]W'Q6+K0
ML*FZ,X&+CW#XZQG!#K-TC+^9.10R6QX=,RJ53$]@TKH*O&0R1-\%[I5/\G2$
M0&A2E[@B([@"@4&@U$U=)F57$GIG*JH'.FK\(E/4N\3F3W[B=DM2"-/JG&O3
MI0VG8!6&"OXO[W!8H^L&T9Y^A,REN6Y(R#<Z1V[V3MZ*=O$!^(?A64;BJ"Q2
MFJ4=U"FZTTA3I)*MT@4]JRI$!CTD&A"E,"7V) .;8(IT 4C%*F4X4IT'H4H"
M'0- 59[BR.@%0JAJ/!4'XBD)4O43%*8Q.H@HF8I1,4#4$!_:'2D8]R@AN'>I
MBWWK"C6;:B,VXEQM^$//O!17-)-XB(2DC D(@91%\*)'0"D)A$3',8X5^$0T
MI-359)TKW@5RHO<^4H_E_P!__'7?U/\ &_>_??W_ (_3IJ9C]7L7SQY(W_"4
MA]F?^///8'^<*?WVJJ_31:QVOY6+\1O]VWM_="LMW\&?]H/_ !M"L>G:_P#.
M-]ZZ@8X'$0+NVE^RWU Z9A^OU)2I:^&CX*>?;MWEA&D:K8CR^7AP74Y 4;F;
M&!<J:AQ4,"1J 13:!2+) (T!</RAZZ6O!:7?\N1/>7W$#'2<3I'ZE)BX)WW:
M/.SAI=7$K*3UNK>=FP8P$6+]0BK_ .3D(HI;MSM=P@NHHS=@4#F :I[*B--7
M&N+XR214T7E-\Q'+^[=$NK@Z@;$Q\>V[A-ZAH/+J\H<W$T[\!11X,JXUN+#E
M_P!W8RO5BFE<%I2CR.>-CH DD];H*&\A((*G+N6;/VVQ1)0IA "F"O73"-)H
M5Z?=/[SEWJWTRL]_,['2F(%XJ3YN(\H ]B+#P;QSZ?\ =&$*9_RZI 9.&7?N
MW;1W=MPVHK!1Q143CVK,S%R"#PO9VC4.AO=IPT8!Q.)7Q7UUO^L>R<Z#:.F/
M+HO>26,9IF%K;R!\A:#)^(\!] :BG Y(6.;(.Q8#*UV1F/+S7R#8[":54@)T
MRSU?>AWS'!J9>0.HLY.@F&T5? U:AI'X.H#4!?7O3N:^@Y/L+W?=G?:;B^,&
M5H;%&0:"M= 6K51$Z2X%2(0IU%#E IPWT,MW"E$@]1$"" 5\.FI&9+K/-6\[
M&[8)/Y8-$/Y4Z@7:CKTXXT4]SB2?=QLPL80$HFQW;P[1I4 !@B'6GX-2R8TI
MW+\Y/5.1C^INY:3G<2'WK?RIC@HF "($,583  "!CB5*I"%/U @B;Z!U#)P7
M/8Q2YD_M!,&P1GO)N0^:7+K#=RJQ1+%P<QQB-IM&3%PE(+C>T+)23\SUVH()
M.A14:D*42AT$#>_4=:YK+EH$51G@MW<O+ERI9> +UN7"KZ):9/AF\5^:*,\U
M\U#24N_FXJ-;1DB4**)(O!>"GO 0 HFJ/AH'O45H&.>X/RP39.+/+*Y>15\6
M[:SH4,<WM8%N3D1R)P;-,B(7/:]]1<B5B22CMA]ZMIS0578.J=MPF:I?#17@
MIY61XD>Q/ Y#Y63P1@G*.:'+%>93QI8-S7H>,1$$_F7R"(=OD&:RA2',0BQT
M@*)J4ZZ*G/BH&M87$#,!:-X[RN><CV'@C,URY MX&F18)A=UW60SAD2V\E"7
M)%%DXB-MQ^50'824>1<A53J"8C@Q1,4 T#)-DTU]BVORBS4KQSXZ97S<I#J3
MAL9V6_N5*&*440?/4EB(M3KJ&$>VT(HN05#==I0$= 26S=4P:<BF4R_*'.&(
MI+AC=U\S4#>5K<H;EMVRKR@(N)38JV?+WS;*]QVU+VN]1 32C!@<I$'I%=QQ
M3J<I@"FA798(A4-&('THJ+Q0CANX$X*%!,X%5I4 +V%A'O[2A4Q !/=3VAT'
M2TQ5..-GJ#*O[,D#W&_.[/EP<HY'!QY.T)^39<N[ZQ/^;+B("*6_0M9L.21>
M7DTF4DDVYYQ@LX( (CN%0@B%*Z3XJ]);QAM ",*_L1Q#O"J)@)MZ9S?9;S 9
M(AQH&Y1,:"8P$_ %=+05[E0$; \'VH*&#>:7*._<[&LAE!1E[P47RWR[AZ[F
M$9;AVB%L8KLUD"D5><I<:::;=.;+(F*EVSB(K /32=Q[5=E9%IJW#O1BLDWP
MUQS8%\7X\:K/6MEVK/7,LU1#XW1(2)=RAFY!Z[15!KMK0:5T%4VM:X@.PJ4(
MA3FIG*U^-O&OF5-OH"6M/,F0K(@KHQ8SC4P6AK.RE=)X"VU8*>*45W,["E$J
MKH#")%"U*4H#UTN0!5Y\$)+@,#VHUI% .4IP*(%.4I@J'6A@ W[@#I"%CW1-
M.=*H$F1N>?("WN5^5\'6T\M.0=1.<</X_P <6A*P:;0MQVO=D&G,WR=Q="RA
M2H2<6R,95(#&W&$M"E$=*<\%D3;Q>F#3$CZ,$=A(Y@(F42;3=L@;=PF !VA\
M('$ $0#V"/4=(0L<Z-A%3DAM9XYIN\4\P< X:24C@QW>TK(6+D.27146>0M^
MW'&+R6/&Z2I2 D*;U5B*!@W )3N4Z^/4R4OI5CU#V>")"<%2IB<=A5BI*$[?
MB GI]E7W[1T*J]E<0AC9%R9R8M;E+BC L9DFVT&N9K9RO=S625M%NH: 1LU%
M)>%A_,*[SN.AA!0QJ&-728JRT-,0!X#WHD=NI2"$##IRCA%_*ILV/S=ZU0!N
MW>21FY"O7:#8!-V$%G6XY2U': Z4J!_!"OMWE'EVY^9G(; +JYD(^WL:9 Q5
M"V>A%V.M*$=QERV<WNN?:7=/E !CBK'54*W6W 0OPE\=(K[((WV@<[[6/Q17
M$C(^7(FT(5$IC&!),3"&\U*_$'4XE3,-1#W:< J4<; Y P=\WN2$;A?E;R =
MRUIR;/C1R-N6QEL?J6\LU"ZL>6ZY@6ZZ+!^J)7!;@<A*F%O0PE4,7ZN@FJM7
M4;(Y UN5*HG7Z>&'_%5U_P#,9^GOZB/\T?Z+?=_Q[^"\="K8^]1SGGIK\?%7
MCM4WJ0\:$C*.G"ADC9-QP!DS'6.84S -Q@(&((T&OM#4&AG[WP7K+#\PG41L
M+&CD3G0@- K_ "ZXQP&/V%;?_K3X]_\ ])>,W_2=C?\ ^Y-&AG[WP4G_ /0O
M47_Z'SK_ /'7/_(78/33X[]/^TFXU5]M,FXU_<_Y2^&DT#M%%DF_,=UG$0:S
MD+G7\N -/_E5WEPQT8X<5P/II\>:A_VDW&C_ *3<:A[O_F3WZ70WM59_S%]5
M3_?<A<Z5_P#:[D?%B<EQ*X%0&.,WV]>.!^?>$+WNZ'(9:6M.T[PM"YI"=M@P
MA\\8O8V"F'SXL<HW 0[G;$J0]:AJQ&0P>7$T[,%Q#K5U@=S5RV[;^?\ E'F7
M;]0/I2W%JZW:U_W:.F:*XYT-4\GGSQDX7YU=PY,G9_P[A'+L7&)EA):8R58U
MM2;J*$ .@D\A)R98.9*/ X@!51 P[*4'3W%A/XFH&G9^M<?Z%<^]:N46//+V
MS;UNO*KWX-MK6[F:T<:.C:8Z]W;5"77]-CC@"H'5]1[BH(_:U(YR=C8Q1,<?
MC$ -=): 4? /Q=1MT4\U?8OJBSZ\<U01$7/(_.<CCD?R,X /&@T%7"?II\=@
M23\OZDO&,2^XN3<:@C3V=O;<QZ_MZ&Z3]JH'<MAY?^8OJAMS)-7(7.-Q:N^R
M/Y7<D-[,=!&2Z+^FEQU.8A5/4EXQ !2[JGRAC<AS&_($0N3[KI^'4D98&G[5
M:K'WOS"<_P!S87,>X\B<WM$CG^9NVW#&L:1AJ\E*CB5*-P9;$=:6),=6W$7-
M#79%P=GQ$8QN.$<MG47-MVK1-,DDQ=,UEVSEJY -Q3D,(" ]-/U^6E#FO++F
MRXGW#G2ZW*=CX)'RN/HR ME;4Y.:<01Q6V#)CM "*(][MF!(PFZ@<?$0#KTI
M]%=0O-75Q6((;ZI<.)R33<68DP+:_(_/&0<?Y#CYG-5Z-K3)F2T$;ZBK@D[?
M+',WB=IJ2MJMG1Y.UDW+1584?,))@X* B6H%'3>*N&0F/26G3VK;><;(L^_;
M ?V[?UU+VA:ZLE /'DRWN)K;!R2#";CG<(W6E7A1032<S*#<@)B("L<Q4PJ)
M@#2<%!&7-<2RI*UC;=A\:V_**Z;Q@[GQ\OR?0QC#6U?41%W9;Q\D.[#+(E>0
MLO?%HLW03B:!9 O;:/UT"D.F(IE,.A-=ZA;V!;SR''6E(V9<;2_W=OMK'7@Y
M%&[EKC>MF,"6VC,EBS(R[I\HBQ0C3L1."ZBQBIIIU,(A32X<4D!D8\G/!-9P
MO@+#MGV]BY[8>9']S8XAA%YB:#:Y'BIS'ZZ;\SA>.9VX]8%,$_%Q[-3ML>VN
MJ!42] $-(%,YY.8HG+Y0B<?R..+SCLP/+93Q@^@9%*_5;SD647:R5NKI"25^
M=RLFLV9,8HB)JG4543*2@")@IH3&%P>"VNKN31;&P-Q(LR0X\RJ^4[=NZ/@
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MU630I&.%"J@82@*?4-"LS2.<X%S2#3L1"_)69_G$!_,E?XRQ_H[^3]Y_,/\
*YGZ=&*AU#L7_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
